

|  |                                 |   |                                |   |
|--|---------------------------------|---|--------------------------------|---|
| <b>AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT</b>  |                                 |   | 1. CONTRACT ID CODE            | PAGE OF PAGES<br>1   37                                   |
| 2. AMENDMENT/MODIFICATION NO.<br>00008   | 3. EFFECTIVE DATE<br>09/13/2023 | 4. REQUISITION/PURCHASE REQ. NO.<br>000HCVG1-2023-80797 | 5. PROJECT NO. (If applicable) |   |
| 6. ISSUED BY<br>Centers for Disease Control and Prevention (CDC)<br>Office of Acquisition Services (OAS)<br>2900 Woodcock Blvd, MS TCU-4<br>Atlanta, GA 30341-4004 | CODE<br>8219                    | 7. ADMINISTERED BY (If other than Item 6)               |                                | CODE<br>8219  |
| 8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)<br>E3HEALTH SOLUTIONS, LLC<br>602 STRADA CIR<br><br>MANSFIELD, TX 76063-               |                                 |   | (√)                            | 9A. AMENDMENT OF SOLICITATION NO.                         |
|  |                                 |   |                                | 9B. DATED (See Item 11)                                   |
|  |                                 |   | X                              | 10A. MODIFICATION OF CONTRACT/ORDER NO.<br>75D30122C13955 |
|  |                                 |   |                                | 10B. DATED (See Item 13)<br>06/01/2022                    |
| CODE ZAFVWPWKFTFB8   | FACILITY CODE                   |   |                                |   |

## 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

- The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers \_\_ is extended, \_\_ is not extended. Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:
- (a) By completing Items 8 and 15, and returning \_\_\_ copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

## 12. ACCOUNTING AND APPROPRIATION DATA (If required)

9390LR9 2512 2023 75-X-0140 C6R6111101 Increase \$57926460.00

## 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

|     |   |
|-----|---|
| (√) | A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.  |
|     | B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). |
| X   | C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:<br>FAR 43.103 (a) (3) Reflect other agreements of the parties modifying the terms of contracts   |
|     | D. OTHER (Specify type of modification and authority)   |

E. IMPORTANT: Contractor  is not,  is required to sign this document and return 1 copies to the issuing office.

## 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

Vendor POC: Kyle Alexander - (b)(6)  
 Contract COR: Mary Hoelscher - mzl@cdc.gov - 404.639.5446  
 OFR/OAS: Eric Lyons - kpy2@cdc.gov - 770.488.2949

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

|   |                               |  |   |
|---|-------------------------------|--|---|
| 15A. NAME AND TITLE OF SIGNER (Type or print)<br>Kyle Alexander President & COO       |                               | 16A. NAME OF CONTRACTING OFFICER<br>Lauren Peel  |   |
| 15B. CONTRACTOR OFFEROR<br>Kyle Alexander<br>(Signature of person authorized to sign) | 15C. DATE SIGNED<br>9/15/2023 | 16B. UNITED STATES OF AMERICA<br>BY Lauren Peel -S<br>(Signature of Contracting Officer) | 16C. DATE SIGNED<br>Digitally signed by Lauren Peel -S<br>Date: 2023.09.15 17:12:40 -04'00' |

In accordance with the Advance Agreement distributed on September 1, 2023, and pursuant to authority cited in Block 13C, this Modification serves to:

1. Incorporate updated Section C - Statement of Work as set forth herein to add Vaccination Services.
2. Update Section B to add Vaccination Services as follows:
  - a. Add Option Period 1.1 (09/13/2023 – 09/30/2024) Items:
    - i. CLIN 1003 Vaccination Services, is added and funded with an extended price and funded amount of (b)(4)
    - ii. CLIN 1004 Vaccination Services: Program Management is added and funded with an extended price and funded amount of (b)(4) and
    - iii. CLIN 1005 Option: Additional Vaccination Services is added with an extended price of (b)(4) and funded amount of (b)(4)
  - b. Add Option Period 2.1 (10/01/2024 – 12/31/2024) Items:
    - i. CLIN 2003 Vaccination Services, is added with an extended price of (b)(4) and funded amount of (b)(4) and
    - ii. CLIN 2004 Vaccination Services: Program Management is added with an extended price of (b)(4) and funded amount of (b)(4)
3. Update Section J – List of Attachments to add: Attachment J.1.b – Vaccination Data Reporting Requirements; and Attachment J.1.c. – Summary of Outreach Conducted for Bridge Access Program.
4. Total contract funded amount is increased by \$57,926,460.00 from (b)(4) to (b)(4)
5. Total contract value is increased by (b)(4) from \$ (b)(4) to (b)(4)

All other terms and conditions of the contract remain unchanged and in full force and effect.

**Section B - Supplies Or Services and Prices/Costs****Base Period (06/01/2022 – 11/30/2023) Items:**

| ITEM | SUPPLIES / SERVICES   | QTY / UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---|------------|------------|----------------|
| 0001 | ICATT Testing Services<br>in accordance with the statement of work. | 1 Job      | (b)(4)     |                |

**Base Period Additional Testing (06/01/2022 – 11/30/2023) Items:**

| ITEM   | SUPPLIES / SERVICES   | QTY / UNIT | UNIT PRICE | EXTENDED PRICE |
|--------|---|------------|------------|----------------|
| 0002   | ICATT Additional Testing<br>This is an Optional Line Item that may be exercised at any point during the delineated period of performance, and may be exercised more than once so long as the total value does not exceed 250% of the referenced core task CLIN. | 1 Job      | (b)(4)     |                |
| 000201 | ICATT Additional Testing<br>- Repatriation Testing<br><br>PoP: 04/25/2023 - 11/30/2023  | 1 Job      | (b)(4)     |                |

**Base Period NIH Recover Linkage (02/13/2023 – 05/31/2023) Items:**

| ITEM | SUPPLIES / SERVICES  | QTY / UNIT            | UNIT PRICE | EXTENDED PRICE |
|------|--|-----------------------|------------|----------------|
| 0003 | Digital Link to NIH Recover Website<br>Link Website/Test Reports to HHS Programs   | 1 Job                 | (b)(4)     |                |
|      | Line(s) Of Accounting:<br>9390L7Z 2512 2023 75-23-0943 5623RF1101<br>(b)(4)  |                       |            |                |
| 0004 | Informational Materials Link to HHS Prog<br>Informational Materials Link to HHS Programs<br>108 each, (b)(4) per location/month - 27<br>locations x 4 months | 108 Each              | (b)(4)     |                |
|      | Line(s) Of Accounting:<br>9390L7Z 2512 2023 75-23-0943 5623RF1101<br>(b)(4)  |                       |            |                |
| 0005 | In Person Link to HHS Programs<br>In Person Link to HHS Programs<br>108 each, (b)(4) per location/month - 27<br>locations x 4 months                         | 108 Each per<br>Month | (b)(4)     |                |
|      | Line(s) Of Accounting:<br>9390L7Z 2512 2023 75-23-0943 5623RF1101<br>(b)(4)  |                       |            |                |

**Option Period 1 (12/01/2023 – 05/31/2024) Items:**

| ITEM | SUPPLIES / SERVICES   | QTY / UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---|------------|------------|----------------|
| 1001 | ICATT Testing Services<br>in accordance with the statement of work. | 1 Job      | (b)(4)     |                |

|      |  |       |        |
|------|--|-------|--------|
| 1002 | ICATT Additional Testing<br>This is an Optional Line Item that may be exercised at any point during the delineated period of performance, and may be exercised more than once so long as the total value does not exceed 250% of the referenced core task CLIN | 1 Job | (b)(4) |
|------|--|-------|--------|

**Option Period 1.1 (09/13/2023 – 09/30/2024) Items:**

| ITEM | SUPPLIES / SERVICES   | QTY/UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---|----------|------------|----------------|
| 1003 | <b>Vaccination Services</b><br>Services in accordance with Section C<br>Period of Performance: 09/13/2023 – 9/30/2024   | 1 Job    | (b)(4)     |                |
|      | Line(s) Of Accounting:<br>9390LR9 2512 2023 75-X-0140 C6R6111101<br>(b)(4)  |          |            |                |
| 1004 | <b>Vaccination Services: Program Management</b><br>Services in accordance with Section C<br><br>(b)(4)<br><br>Period of Performance: 09/13/2023 – 9/30/2024   | 1 Job    | (b)(4)     |                |
|      | Line(s) Of Accounting:<br>9390LR9 2512 2023 75-X-0140 C6R6111101<br>(b)(4)  |          |            |                |
| 1005 | <b>Option: Additional Vaccination Services</b><br><br>This is an Optional Line Item that may be exercised at any point during the delineated period of performance and may be exercised more than once so long as the total value does not exceed 230% of the referenced core task CLIN.<br><br>Period of Performance: 09/13/2023 – 9/30/2024 | 1 Job    | (b)(4)     |                |

**Option Period 2 (06/01/2024 – 11/30/2024) Items:**

| ITEM | SUPPLIES / SERVICES   | QTY / UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---|------------|------------|----------------|
| 2001 | ICATT Testing Services<br>in accordance with the statement of work.   | 1 Job      | (b)(4)     |                |
| 2002 | ICATT Additional Testing<br>This is an Optional Line Item that may be exercised at any point during the delineated period of performance, and may be exercised more than once so long as the total value does not exceed 250% of the referenced core task CLIN. | 1 Job      | (b)(4)     |                |

**Option Period 2.1 (10/01/2024 – 12/31/2024) Items:**

| ITEM | SUPPLIES / SERVICES | QTY/UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---------------------|----------|------------|----------------|
|------|---------------------|----------|------------|----------------|

|      |  |       |        |
|------|--|-------|--------|
| 2003 | <b>Vaccination Services</b><br>Services in accordance with Section C<br>Period of Performance: 10/01/2024 – 12/31/2024                                       | 1 Job | (b)(4) |
| 2004 | <b>Vaccination Services: Program Management</b><br>Services in accordance with Section C<br><br>(b)(4)<br><br>Period of Performance: 10/01/2024 – 12/31/2024 | 1 Job | (b)(4) |

**Option Period 3 (12/01/2024 – 05/31/2025) Items:**

| ITEM | SUPPLIES / SERVICES   | QTY / UNIT | UNIT PRICE | EXTENDED PRICE |
|------|---|------------|------------|----------------|
| 3001 | ICATT Testing Services<br>in accordance with the statement of work.   | 1 Job      | (b)(4)     |                |
| 3002 | ICATT Additional Testing<br>This is an Optional Line Item that may be exercised at any point during the delineated period of performance, and may be exercised more than once so long as the total value does not exceed 250% of the referenced core task CLIN. | 1 Job      | (b)(4)     |                |

**B.1.1 Unit Pricing**

**Testing Services Pricing**

| Test Type per Setting  | Unit                 | Base Period | Option 1 | Option 2 | Option 3 |
|--|----------------------|-------------|----------|----------|----------|
| Swab and Send- Pharmacy / Retail   | Per Test             | (b)(4)      |          |          |          |
| Swab and Send- Pharmacy / Retail Multiplexed   | Per Test             |             |          |          |          |
| Swab and Send- Non-Pharmacy/Retail   | Per Test             |             |          |          |          |
| Swab and Send (b)(4)   | Per Test             |             |          |          |          |
| (b)(4)   |                      |             |          |          |          |
| Swab and Send/Retail Multiplexed (test cost reimbursed by HRSA, CMS, or private insurance reimbursement) | Per Test             |             |          |          |          |
| Unobserved self-collection and testing – Distributed   | Per Test Distributed |             |          |          |          |
| Unobserved self-collection and testing – Resulted  | Per Test Resulted    |             |          |          |          |
| Unobserved self-collection and Multiplexed testing - Distributed   | Per Test Distributed |             |          |          |          |
| Unobserved self-collection and Multiplexed testing - Resulted  | Per Test Resulted    |             |          |          |          |

|  |            |        |
|--|------------|--------|
| POC NAAT- Pharmacy / Retail  | Per Test   | (b)(4) |
| POC NAAT- Pharmacy /Retail (test provided by USG)  | Per Test   |        |
| POC NAAT- Non-Pharmacy/Retail  | Per Test   |        |
| POC NAAT- Non-Pharmacy/Retail (test provided by USG)   | Per Test   |        |
| Extended hour testing  |            |        |
| Sample Accessioning and Shipping for further characterization  | Per Test   |        |
| Testing Support Services (environmental support for non-English speakers, elderly, young children, people with disabilities, etc.) | Per Test   |        |
| Confirmatory POC testing at Federally Supported Sites (test provided by USG)   | Per Test   |        |
| Point of Care Antigen Testing at Surge sites and Federally Supported Sites (test provided by USG)                                  | Per Test   |        |
| Low Volume Surge Site Infrastructure Management Fee  | Per Test   |        |
| Standard Surge Site Infrastructure Management Fee  | Per Test   |        |
| Point of Care Antigen Testing  | Per Test   |        |
| Point of Care Antigen Multiplexed Testing  | Per Test   |        |
| Point of Care Antigen Testing (test provided by the USG)   | Per Test   |        |
| Diagnostic Sequencing  | Per sample |        |

(b)(4)

**Vaccination Services Pricing**

| Vaccination Service                 | Price  | Unit            |
|-------------------------------------|--------|-----------------|
| Vaccine Administration              | (b)(4) | Per Vaccination |
| Vaccine Administration – Cost Share |        | Per Vaccination |

**B.1.2 ICATT Vulnerable Population Testing, Reimbursement Shift to Private or Public Insurance, Low-Access Population, and Low-Vaccination Coverage Population Payments\***

|                                   | Price  | Unit   |
|-----------------------------------|--------|--|
| Vulnerable Population FFP Payment | (b)(4) | Per Qualifying Test <span style="background-color: #cccccc;">(b)(4)</span> |

|  |        |                        |        |
|--|--------|------------------------|--------|
| Low-Access Population Per Dose Payment           | (b)(4) | Per Qualifying Vaccine | (b)(4) |
|  |        | Per Qualifying Vaccine | (b)(4) |
| Low-Access Population Site Stand-Up Payment      |        | Per New Site           | (b)(4) |
|  |        | Per New Site           | (b)(4) |
| Low-Vaccination Population Per-Dose Payment      |        | Per Qualifying Vaccine | (b)(4) |
|  |        | Per Qualifying Vaccine | (b)(4) |
| Low-Vaccination Population Site Stand-Up Payment |        | Per New Site           | (b)(4) |
|  |        | Per New Site           | (b)(4) |

(b)(4)

\*Each qualifying vaccination is only eligible for either the low-access population per dose payment or the low-vaccination population per dose payment, and each qualifying vaccination site is only eligible for either the low-access population per site payment or the low-vaccination population per site payment. Site stand-up payments are only applicable to the establishment of new sites in those areas and existing sites would not qualify

**B.1.3 ICATT Linkage to other HHS Programs (Ends 05/31/2023)**

|   | Price  | Unit  |
|---|--------|---|
| Digital Link Website/Test Reports to HHS Programs | (b)(4) | One-Time Fee billable upon execution of this modification |
| Informational Materials Link to HHS Programs      |        | Per Location Per Month                                    |
| In-Person Engagement Link to HHS programs         |        | Per Location Per Month                                    |

**B.2 Options for Additional Services – Separately Priced Line Items**

The Contractor shall provide additional support if the Government has a requirement for it. Additional support is included as separately priced Contract Line Item Numbers (CLINs) identified in the Schedule B and described below. The optional CLIN may be exercised more than once up to the total amount listed for each CLIN.

If Additional Services are required, the Government will determine the estimated level of effort (LOE) that is needed. The estimated LOE will be provided to the Contractor for its confirmation of the total. The Contracting Officer may exercise the option by written notice to the Contractor within the period of performance of the CLIN associated with the option line item as shown in the schedule above. The exact period of performance for the option for Additional Services will be established at the time it is exercised and may be for a different period of time than other line items in this contract. The vendor will be notified in

writing, by letter or email, at least 7 days before the option is exercised. After that written notification, a funded, bilateral modification will be issued to formally exercise the option or options.

The Government reserves the right not to exercise any Additional Services CLINs if no Additional Services are required during the performance of this contract.

**B.2.a. Additional Testing Services:**

Additional Testing Services are included as separately priced Contract Line Item Numbers (CLINs) X002 identified in the Schedule B.

**B.2.b. Additional Vaccination Services:**

**B.2.b.1.** Additional Vaccination Services (period of performance 09/13/2023 – 09/30/2024) are included as separately priced Contract Line Item Number (CLIN) 1005 identified in the Schedule B.

**B.3 Contract Points of Contact**

Vendor POC: Kyle Alexander [REDACTED] (b)(6)  
Contract COR: Mary Hoelscher – mzr1@cdc.gov - 404.639.5446  
OFR/OAS: Eric Lyons - kpy2@cdc.gov - 770.488.2949  
OFR/OAS secondary contact: Samantha Bily - qnb7@cdc.gov – 404.498.2150



## Section C - Description/Specification/Work Statement

### SECTION 1 – BACKGROUND

On March 13, 2020, the President declared a national emergency concerning COVID- 19 under section 501(b) of the Robert T. Stafford Disaster Relief and Emergency Assistance Act, 42 U.S.C. 5121- 5207 (the “Stafford Act”). The novel coronavirus (SARS-CoV-2) is a highly contagious pathogen that is responsible for the current worldwide pandemic of COVID-19 disease. To aggressively address this disease, an immediate deployment of critical public health assets and supports was required to decrease transmission of the virus and to provide medical care for impacted communities.

Initially, the federal government implemented new policies to streamline payment for pharmacy testing to more quickly diagnose individuals who may be infected with SARS-COV-2. Early diagnosis has a direct impact on saving lives and reducing the spread of COVID-19 disease. The support provided by the federal government allows private companies to scale operations and dramatically increase COVID- 19 testing access and capacity by removing the complexity and uncertainty associated with billing.

In March 2020, under the Office of the Surgeon General, the US Government established the Community Based Testing Site (CBTS) program to support patient accessibility to no-cost diagnostic testing in pharmacies and community surge testing sites. This program was converted under the inter-agency Testing and Diagnostics Workgroup (TDWG) to the Increasing Community Access to Testing (ICATT) Program. ICATT provides no-cost testing in locations with a high social vulnerability index (SVI), elevated rates of COVID-19 incidence, and/or lower rates of COVID-19 vaccine uptake. Under this contract, patients do not receive a bill for the test and do not pay any fee related to test processing, evaluation, or handling. Evidence shows that when local no-cost opportunities are available there is an increase in the number of individuals who seek and receive testing.

Community pharmacy and surge testing sites are maintained through a public/private partnership with various national pharmacy chains, independent pharmacies, and laboratories. Between April 2020 and November 2021, through various contracting actions, the ICATT program has directly supported the performance of more than 25.5 million SARS-CoV-2 tests through the more than 10,000 pharmacies and community sites in all 50 states, Washington DC, and Puerto Rico. As of November 2021, 53% of the ICATT sites are in high SVI communities, and 40% of all ICATT tests performed are for racial and ethnic minorities. ICATT has support over 790 surge sites since April 2020. As of December 2021, the program has 32 active surge sites. At present, the ICATT program performs an estimated 5% of all national testing and based on a recent Rockefeller Foundation survey, parents indicated that pharmacies are the most favored location for obtaining a test.

COVID-19 vaccinations are critical in preventing a surge in COVID-19 cases due to a variant strain. During the COVID-19 pandemic, the Federal Retail Pharmacy Program (FRPP) administered COVID-19 vaccines at no-cost to eligible patients under a federal vaccine procurement contract. On May 11, 2023, the public health emergency (PHE) ended, which will have an impact on testing and administration of vaccinations for the uninsured and underinsured, one of the most vulnerable populations. Manufacturers will commercialize the vaccines which will result in a sharp price increase for vaccines. Post-PHE, due to the reversion to pre-pandemic policies and authorities, the uninsured and underinsured may not have the ability to afford the unsubsidized cost of vaccinations.

### SUBSECTION A – DEFINITIONS

|                                       |  |
|---------------------------------------|--|
| <p><b>Communities of Interest</b></p> | <p>Supporting communities of interest by providing no-cost access to COVID-19 testing and vaccination is the primary mission of the ICATT Program. Communities of interest meet one or more of the following criteria:</p> <p>For Testing Services:</p> <ul style="list-style-type: none"> <li>• Are located in a moderate or high social vulnerability index (SVI) census tract (SVI rating is greater than 0.5); pharmacy locations that are not located in moderate- or high-SVI census tracts but serve moderate- or high-SVI census tracts are included in this consideration;</li> <li>• Greater than 36% of the demographic composition of the county identifies as non-white or</li> </ul> |
|---------------------------------------|--|

|                                    |  |
|------------------------------------|--|
|                                    | <p>Hispanic</p> <ul style="list-style-type: none"> <li>• Are at a greater risk of SARS-CoV-2 transmission due to the 7-day case rate exceeding 25 per 100,000;</li> <li>• Are located in a testing desert (see definition); and/or</li> <li>• Are at greater risk of poorer health outcomes resulting from COVID-19 disease where vaccination rates are less than half the national average.</li> </ul> <p>For Vaccination Services:</p> <ul style="list-style-type: none"> <li>• Are located in a low-access area or low-vaccination coverage area (see definitions)</li> </ul> |
| <b>End-To-End Testing Process</b>  | All aspects of testing and support services including patient registration/scheduling, application of screening criteria, ordering of the test by a licensed healthcare practitioner, operation of the testing site, transportation/delivery of test sample to lab (if needed based on testing model), conduct the test or cover payment for conducting the test, notification of results to patients, input as required into the HHS Protect system data, and report positive and negative cases as directed by the relevant state and local Departments of Health.             |
| <b>ESDTF</b>                       | Expansion of Screening and Diagnostics Taskforce   |
| <b>Federally Supported Testing</b> | Federally supported testing is a rapid stand-up of COVID-19 testing at sites where the federal government has determined that a testing need exists that otherwise is not covered by existing pharmacy testing capacity or surge sites sponsored by other public health jurisdictions.   |
| <b>HHS Protect</b>                 | A secure platform for authentication, amalgamation, and sharing of healthcare information.   |
| <b>ICATT</b>                       | Increased Community Access to Testing Team. Provides no-cost testing to under-resourced populations. Operates in pharmacies, congregate settings, surge sites, hot spots, and priority locations.  |
| <b>Insurance Denial</b>            | Claims for services for insured individuals (either when presented at the time of service or as a result of insurance discovery) not reimbursed by the insurance provider due to lapsed or invalid insurance, improper submission by the vendor or service is not covered by the insurance provider. For testing services, Insurance Denials are not reimbursed by the contract. For Vaccination Services, only denials due to lapsed or invalid insurance coverage are eligible for reimbursement under the contract.   |
| <b>Insurance Discovery</b>         | The process the Contractor must undertake prior to invoicing ICATT for services administered as set forth in Section 4.2.N.  |
| <b>Low Access Area</b>             | An area in which a significant number of uninsured and underinsured persons are far enough from the closest pharmacy, health center, or health department site as to make it difficult for those persons to travel to the nearest site to access a vaccination service. For example, these areas may be defined as census tracts that are at least 1 mile in urban areas, 2 miles in suburban areas, and 10 miles in rural areas away from the nearest vaccination site. CDC will update a list of low-access areas each month and distribute it to participating vendors.       |
| <b>Low Vaccination Area</b>        | An area in which a significant number of uninsured and underinsured persons have not yet been vaccinated. This will be defined, for example, as census tracts that are in the lowest 50th percentile of historical COVID-19 vaccination coverage and where more than 10% of the population is uninsured. The definition of low-vaccination area will be updated over time to include more recent COVID-19 vaccine uptake data. CDC will update a list of low-vaccination coverage areas each month and distribute it to participating vendors.                                   |
| <b>NAAT</b>                        | Nucleic Acid Amplification Test  |
| <b>Outreach</b>                    | Outreach includes communications, promotional materials, partnerships, and educational events conducted to reach communities of interest. Activities conducted should aim to improve vaccination coverage, access, and awareness in these communities.   |
| <b>PREP Act</b>                    | The Public Readiness and Emergency Preparedness Act (PREP Act) authorizes the Secretary of the Department of Health and Human Services (Secretary) to issue a PREP Act declaration. The declaration provides immunity from liability (except for willful misconduct) for claims: <ul style="list-style-type: none"> <li>• of loss caused, arising out of, relating to, or resulting from administration or use of</li> </ul>   |

|  |  |
|--|--|
|  | <p>countermeasures to diseases, threats and conditions</p> <ul style="list-style-type: none"> <li>determined by the Secretary to constitute a present, or credible risk of a future public health emergency</li> <li>to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures</li> </ul>   |
| <b>Site Status</b>   | <b>Confirmed</b> – Testing site that has been approved but has not reached Go Live date.   |
|  | <b>Inactive</b> – Testing site that has not submitted results in HHS Protect for 30 days.  |
|  | <b>Live</b> – Testing site that is currently providing testing.  |
|  | <b>Transition/Closed</b> – Testing site identified by Contractor that is no longer providing testing. Contractors cannot bill for testing that occurs after the Close Date for closed sites.   |
| <b>SVI</b>   | Social Vulnerability Index. Social vulnerability refers to the potential negative effects on communities caused by external stresses on human health. Such stresses include natural or human-caused disasters, or disease outbreaks. SVI uses 15 U.S. census variables to help local officials identify communities that may need support before, during or after disasters. See: <a href="https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html">https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html</a> for more information |
| <b>STLT</b>  | State, Tribal, Local, or Territorial Public Health Agencies  |
| <b>TDWG</b>  | Testing and Diagnostics Working Group  |
| <b>Testing Desert</b>  | Census tract that is at least 10 miles away from a testing site.   |
| <b>Testing Sites</b>   | <b>Border</b> – Testing at migration related sites such as an airport, border station, or quarantine station.  |
|  | <b>Community</b> – Long term non-pharmacy testing site (may be a brick-and-mortar store or fixed site in a community)  |
|  | <b>Congregate</b> – Congregate facilities such as nursing homes or schools   |
|  | <b>Pharmacy</b> – Brick-and-mortar pharmacy testing sites including Pharmacy drive-thru locations  |
|  | <b>Non-Pharmacy/Retail Sites</b> - Off-site testing of a short duration to include surge, community, congregate, Federally Supported sites and or similar locations not associated with permanent structures.  |
|  | <b>Pop-up/stand-up sites</b> – see surge with management fee   |
|  | <b>Surge Testing</b> – Short-term remote testing events (e.g., parking lots or other public venues) that are held in response to an STLT public health agency’s determination that a change in local case rates indicates a greater need increased testing in the area. Surge testing events are typically held for one to two weeks at a time.  |
|  | <b>Surge with infrastructure management</b> – Surge testing site with management fee. Fee is added when Contractor provides Surge Site Infrastructure Management services. (see section 4.11)  |
| <b>Surge without infrastructure management</b> – Surge testing site without management fee. Fee is not added if another entity provides infrastructure management (such as a generator, Wi-Fi, tent, tables, etc.) |  |
| <b>Testing Methods</b>   | <b>Genomic Sequencing</b> - next generation sequencing performed to identify specific variants of SARS-CoV-2 in clinical specimens; in the context of this document, it can refer to sequencing done for genomic surveillance purposes (see CDC definition) or diagnostic purposes to detect variants of clinical relevance. Sequencing for diagnostic purposes must be performed using a method compliant with CLIA regulations.  |
|  | <b>Confirmatory Testing</b> - Confirmatory POC testing, typically NAAT, is performed to confirm the results of a POC result that mismatches the patient’s symptoms. Used only in certain settings to guide patient care or processing.   |

|                                |   |
|--------------------------------|---|
|                                | <p><b>Unobserved-self collection</b> - Samples are self-collected, without observation from a medical professional, returned to a drop-off location or mailed followed by laboratory PCR testing.</p> <p><b>Multiplexed Testing</b> – Diagnostic tests which detect two or more targets in a single test; in the context of this document, it refers to two or more pathogens such as SARS-CoV-2 and Influenza (Type A and Type B).</p> <p><b>Over-the-counter (OTC) tests</b> – Diagnostic tests that have been authorized by FDA for use without a prescription.</p> <p><b>Point-of-care (POC) Testing</b> - Diagnostic tests performed at or near the place of specimen collection, Test performed could be antigen based or NAAT based.</p> <p><b>Polymerase Chain Reaction (PCR)</b> – Diagnostic tests that detect SARS-CoV-2 genetic material; in the context of this document and other solicitation materials, it includes both reverse transcription polymerase chain reaction and isothermal amplification POC or laboratory-based testing methods.</p> <p><b>Pooled Sample Testing</b> - Combining the same type of specimen from several people and conducting one test on the combined pool of specimens to detect SARS-CoV-2. Pooled tests that return positive results require each specimen in the pool to be retested individually to determine which individual(s) are positive. The advantages of pooling include preserving testing reagents and resources, reducing the amount of time required to test large numbers of specimens (increasing throughput), and lowering the overall cost of testing. The optimal pooling strategy depends on the incidence of infection in the community, and pool size need to be adjusted accordingly.</p> <p><b>Swab and Send</b> –Observed self-collection kit for sample collection followed by laboratory PCR testing.</p> |
| <b>Turnaround Time (TAT)</b>   | The difference between Date of Sample Collection and Date of Testing Result as recorded in HHS Protect or other required federal reporting systems.   |
| <b>US Regions</b>              | <p>For the purposes of the ICATT program, there are seven (7) US regions:</p> <ol style="list-style-type: none"> <li>1. New England (Northeast): Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont</li> <li>2. Mid-Atlantic: Delaware, Maryland, New Jersey, New York, Pennsylvania, and Washington, D.C.</li> <li>3. South: Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, and West Virginia</li> <li>4. Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin</li> <li>5. Southwest: Arizona, New Mexico, Oklahoma, and Texas</li> <li>6. West: Alaska, Colorado, California, Hawaii, Idaho, Montana, Nevada, Oregon, Utah, Washington, and Wyoming</li> <li>7. Other: U.S. territories, protectorates, or freely associated states.</li> </ol>   |
| <b>Underinsured Individual</b> | Vaccination Services: An adult, eighteen years of age or older, who meets the requirements set forth in Section 4.2.N.  |
| <b>Uninsured Individual</b>    | Vaccination Services: An adult, eighteen years of age or older, who meets the requirements set forth in Section 4.2.N.  |
| <b>Vaccination Services</b>    | The administration of COVID-19 vaccines, including boosters, to eligible Uninsured and Underinsured adults eighteen years of age or older.  |
| <b>Voucher</b>                 | <ul style="list-style-type: none"> <li>• A document or digital document (on a phone) that contains the patient information and scheduled testing time. The test taker presents the printed voucher to the Contractor to indicate that they have registered for a test. The test voucher is combined with the collected sample to link the patient to their sample and track the sample to the next step in the testing process, thereby serving as a laboratory requisition. The test voucher can be a digital document on a phone. In this case, the test taker presents the digital voucher, and the Contractor will print out a physical voucher to be combined with the test sample. The voucher has no monetary value.</li> <li>• A test voucher can also be a piece of paper with a registration number that allows a test taker to register for a test using pharmacy sites that are not funded by the Government.</li> </ul>  |

|                             |  |
|-----------------------------|--|
|                             | In this way, the government can support testing in pharmacies to populations at higher risk of COVID-19 disease or poorer health outcomes that are not located in high SVI areas or supported by the Government. Using the registration number on the voucher, the test taker can register for a no cost test instead of charging the test to the patient's health care insurance. The voucher has no monetary value.  |
| <b>Wrap-around Services</b> | A testing partner's (Contractor) ability to conduct both of the following at the time that the result is communicated to the patient: <ol style="list-style-type: none"> <li>1. Connect patients who receive positive or indeterminant COVID-19 test results with care linkages and/or available therapeutic interventions</li> <li>2. Provide COVID-19 vaccination access and informational resources to patients who receive negative COVID-19 test results.</li> <li>3. Linkage to the other HHS programs to support COVID testing programs.</li> </ol> |

## SECTION 2 – PURPOSE

In this effort, the Expansion of Screening and Diagnostics Task force (ESDTF) at the U.S. Centers for Disease Control and Prevention (CDC), which supports the inter-agency TDWG, seeks to increase equitable access to COVID-19 testing and vaccination through contractual relationships with private sector partners.

## SECTION 3 – SCOPE OF WORK

The ICATT program objectives are achieved through four (4) primary efforts:

1. Testing in pharmacies to ensure equitable access to COVID-19 testing
2. Establishing surge testing sites and provide testing to provide infection control to populations at elevated risk of SARS-CoV-2 transmission
3. Establishing community testing sites and provide testing to increase access to COVID-19 testing in under-resourced communities
4. Administering COVID-19 vaccines to uninsured and underinsured populations to ensure equitable access to vaccines in the period following commercialization

Additionally, the ESDTF ICATT Program will continue to expand testing and vaccination outreach, availability, and effectiveness. As needed, the Government shall increase or decrease the number of testing and vaccination sites supported to adapt to the pandemic response needs. However, at this time it is the intention of the Government to maintain approximately 20,000 ICATT testing sites and to require participating vendors make reasonable efforts to offer vaccination services at all retail pharmacy locations. The number of sites that the ICATT program will maintain may be subject to change as the response to the COVID-19 pandemic continues to evolve.

The Contractor shall sustain surge testing and vaccination capabilities to deploy to disease outbreak zones, including flexible off-site testing and vaccination models to rapidly reach communities of interest. Contractor shall use appropriate testing and vaccination methodologies in accordance with state and federal regulations to provide quality and timely results as described in 4.8.F.

To provide patients access to wrap-around services in addition to testing provided under ICATT, the Contractor shall integrate ICATT testing services with other related COVID-19 vaccination services to the greatest degree possible at each testing site to create a single point of access. These wrap-around services are intended to help reduce morbidity and transmission of this disease. The Contractor shall maintain the capability to provide wrap-around services under this contract. Distribution of informational resources shall be required. Actual distribution of therapeutics if required during performance will be added via a bilateral modification.

The Contractor shall track and report data on testing and vaccination sites, tests and vaccinations performed that enhances the analysis of HHS testing and vaccination data and complements federal disease surveillance and research activities. Unless otherwise state herein, all data collected by the Contractor will be entered into HHS Protect and state IIS systems, if applicable.

The Contractor shall adapt and implement strategies in collaboration with the government to respond to the changing pandemic environment, employ maintenance strategies to ensure testing capabilities are up to date and relevant, and implement efficiencies over time for cost and timeliness of services provided.

The Government acknowledges and agrees that Contractor may utilize subcontractors to carry out Contractor's obligations under this contract, and Contractor acknowledges and agrees that it is responsible for the use of such subcontractors and such subcontractors' compliance with the terms of this contract to the same extent Contractor must comply.

#### **SECTION 4 – TASKS TO BE PERFORMED**

##### **1.) General Tasks and Responsibilities**

The Contractor shall provide the below tasks/services in locations that have been approved by the Government to address the COVID testing needs of individuals in communities of interest covered under the ICATT program. All services shall be provided at no cost to eligible patients.

The Contractor, in accordance with the relevant laws and regulations of state Departments of Health and other state agencies, officials or community partners related to specific site, shall perform the following (collectively, "Services"):

##### *i. Testing Services:*

1. Provide full end-to-end processing of tests including patient registration/scheduling, application of screening criteria, ordering of the test by a licensed healthcare practitioner, operation of the testing site, transportation/delivery of test sample to lab (if needed based on testing model), conduct the test or arrange for the conducting of the test, notification of results to patients, input required HHS Protect system data, and report positive and negative cases as directed by the relevant state and local Departments of Health. See "Specific Tasks" for more details.
2. Test according to specific criteria determined by the Centers for Disease Control & Prevention (CDC) unless otherwise agreed to by the Government.
3. Implement standard diagnostic testing quality assurance and controls per test kit manufacturer guidelines.

##### *ii. Vaccination Services:*

1. Provide vaccinations in accordance with protocols determined by the CDC: <https://www.cdc.gov/vaccines/hcp/admin/admin-protocols.html> and <https://www.cdc.gov/vaccines/covid-19/index.html>
2. Implement standard vaccine quality assurance and controls per manufacturer guidelines and in accordance with protocols established by the CDC: <https://www.cdc.gov/vaccines/hcp/admin/storage-handling.html>
3. Comply with Vaccine Adverse Event Reporting System (VAERS) reporting requirements: <https://vaers.hhs.gov/reportevent.html>
4. Vaccinations in conformance with the CDC Interim Clinical Considerations: <https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html>

Unless otherwise waived, the Contractor shall abide by all Federal and State guidelines, (e.g., Health Insurance Portability and Accountability Act (HIPAA)), needed to protect personal identity information.

##### **2.) Program Management and Staffing**

- A. The Contractor shall provide program management for the operation of the contract and shall provide organization, control systems, quality assurance and reporting procedures.
- B. The Contractor shall ensure all necessary communication on at least a weekly basis with ICATT program representatives on all aspects of the Services locations regarding site status changes, inventory and key staffing and leadership updates, site needs, testing metrics, and risks and issues.
- C. The Contractor shall ensure adequate testing materials are available for operations.

- D. The Contractor shall provide, maintain, and use all information technology (IT) systems necessary for the full discharge of activities required under this contract. Such systems include patient screening and registration, scheduling, chain of custody of specimens and tests, fulfilling public health reporting obligations, patient notification of test results, logistical support (e.g., timely delivery of all required testing related supplies), and capacity to report on all elements described in Attachments J.1 “Data Reporting Requirements.”
- E. Contractor shall report all elements described in Attachment J.1 “Data Reporting Requirements” on at least a daily basis.
- F. When partnering with another entity (e.g., state and local stakeholders, bases, etc.) in providing surge site infrastructure management and operations of event sites, the Contractor shall work with the state and/or local stakeholders to determine the appropriate testing strategies, logistics, site management, and implementation timelines, and operating hours for the sites. The Contractor may coordinate with the state/local Department of Health or other state/local agencies for the purposes of setting up and operating the site to accomplish any of the following: scheduling patients, site logistics, augmenting personnel, augmenting supplies, and augmenting security.
- G. For the purposes of establishing and operating approved sites for scheduling patients, site logistics, augmenting personnel, augmenting supplies, and augmenting security, the Contractor shall coordinate with appropriate state/local Department of Health or other governing state/local agencies to determine the required policies and regulations for conducting ICATT services within their jurisdictions. It is the Contractor’s responsibility to assure all services under this contract comply to these policies and regulations.
- H. Contractor shall maintain sufficient staffing capacity sufficient to maintain hours of operation and service capacity described to meet applicable requirements of sections 1.) and 4.3.A.
- I. Contractor shall ensure that contractor’s sites currently providing no-cost testing supported by other federal agencies and programs (e.g., HRSA and/or ELC) will be excluded from ICATT-participation.
- J. Contractor shall ensure the following:
- a. All Services performed under this contract shall be performed in compliance with Clinical Laboratory Improvement Amendment (CLIA) (including CLIA Certificates or Certificates of Waiver, or CLIA violations and Food and Drug Administration (FDA) regulations (including FDA EUA submissions or amendments).
  - b. All tests and vaccines used in performance of Services under this contract have appropriate FDA Emergency Use Authorization (EUA).
  - c. Compliance with any regulatory barriers or requirements required for successful performance of services (including FDA EUA submissions or amendments, CLIA Certificates or Certificates of Waiver, or CLIA violations at proposed sites).
  - d. Implement insurance discovery processes by the end of the public health emergency (PHE).
  - e. Utilization of the insurance discovery processes that were developed, as required, by the end of the public health emergency (PHE).
- K. The contractor shall provide monthly reports on the above activities including any challenges to implementation.
- L. The contractor shall provide upon request by CDC ad hoc reports to clarify testing and vaccination data as required by the changing nature of the COVID-19 response.
- M. The contractor shall complete a final report at the completion of each period of performance. The final report shall include total testing and vaccination numbers for the period of performance, the report should highlight areas of interest, trends, quality issues, and continuous improvement metrics. The final reports should also include any challenges in the implementation of Section 8.
- N. *Insurance Discovery – Vaccination Services*: Implement the following Insurance Discovery steps for COVID-19 vaccinations prior to administration of Vaccination Services:
1. Through Contractor’s platform, patient completes eligibility assessment. Patient enters medical insurance information or patient attests to having no medical insurance. If no medical insurance is identified, patient will proceed. (Uninsured).
  2. If medical insurance is identified, patient will be prompted to enter medical insurance information before proceeding.
  3. For patients representing as uninsured, Contractor completes medical insurance

- coverage check. If medical insurance is identified, patient is prompted to enter insurance information.
4. For patients with medical insurance, once insurance information is entered:
    - a. Contractor runs medical insurance verification to determine whether insurance provides coverage for COVID-19 vaccination.
      - i. Patients eligible for vaccination without a co-pay are rejected under ICATT (Insured).
      - ii. Patients identified as eligible for COVID-19 vaccination but with cost-share will proceed subject to eligibility requirements, below (Underinsured).
  5. *Eligibility Requirements for Services to be Invoiced under ICATT:*
    - a. **Uninsured Individuals** If the eligibility check is returned showing that the patient does not have active medical plan/pharmacy benefit coverage, the patient is considered an Uninsured Individual and ICATT will be invoiced the Vaccine Administration Fee set forth in Table B.1.1.
    - b. **Insured Individuals:** If the patient has confirmed pharmacy benefit coverage and an adjudicated claim is returned with no cost to the patient, the patient will be considered insured and both the vaccine ingredient fee and the fee for administration will be charged to the pharmacy benefit plan. If the patient has confirmed pharmacy benefit coverage and an adjudicated claim is returned with a message to “Bill Medical Plan” and if Contractor is confirmed to be in-network, the patient will be considered insured and both the fee for the vaccine and the fee for administration will be charged to the medical plan. If the patient does not have pharmacy benefit coverage but has confirmed medical plan coverage (and if Contractor is confirmed to be in-network), and an adjudicated claim is returned with no cost to the patient, the patient will be considered insured and both the vaccine ingredient fee and the fee for administration will be charged to the medical plan.
    - c. **Underinsured Individuals:** If the patient’s pharmacy benefit/medical plan coverage is confirmed, however an adjudicated claim is returned with a cost-sharing amount that must be collected from the patient at the time of service, the patient will be considered to be an Underinsured Individual. Any cost covered by the pharmacy benefit/medical plan coverage is applied to the vaccine ingredient fee and the cost share attributable to the patient will be invoiced to ICATT up to the full value of the Vaccine Administration Fee – Cost Share set forth in Table B.1.1
    - d. **Individuals with No Coverage at selected pharmacy:** If the patient’s pharmacy benefit/medical plan coverage is confirmed but the adjudicated claim is either 1) rejected with indication that the product or service is not covered; 2) if the adjudicated claim is returned with a message to bill a medical plan for which Contractor is not confirmed as in-network; or 3) for any other reason was not returned as a paid claim, the patient is presumed to have coverage elsewhere. In these instances, the patient will be offered alternative options including the option to self-pay or to follow up with their health plan to determine where the service may be covered.
    - e. **Insurance Denial:** Contractor shall not invoice the Government under



this contract for claims denied for reasons other than lapsed or invalid insurance coverage.

### 3.) Site Locations

#### Testing Services Site Locations

- A. The testing locations are sites that have been determined to benefit from enhanced access to testing, including pharmacies, community sites, and surge sites. It is the Government's desire to establish and maintain up to 20,000 approved test sites at locations covered by the ICATT program. From time to time, the Government may identify locations to be added, changed, and/or removed. When the Government requests a change and it is within the Contractor's locations covered under this Contract, upon mutual agreement of the Parties, the Contractor may make the change and/or add the location. The government will provide a one (1) week notice to expand or contract surge sites once all information to implement the site has been received by the contractor. The Contractor shall operate and sustain a minimum of 1,000 pharmacy, community and / or retail testing sites concurrently. The government will provide four (4) weeks notice for expansion or contraction of pharmacy sites. While due to budget constraints and program needs the Government may permit Contractor to operate fewer than 1,000 sites, the Contractor shall be able to scale up to this level with two weeks' notice if operating below the minimum at the direction of the Government. These sites shall meet the following criteria:
- i. A minimum of 200 sites shall be in each of any three US regions or a minimum of 100 sites in each of the contiguous U.S. regions (regions one through six; see "US Regions" in definitions)
  - ii. At least 50% of sites should be located in intermediate to high social vulnerability index census tract areas or, if not feasible, at least 500 sites should be located in such areas
  - iii. At least 10% of sites shall operate under extended hours based on testing demand. The Government defines extended hours as at least 3 hours before 9 AM or after 5 PM. These sites may provide any test method
  - iv. During regular operations, the Contractor shall be prepared to meet a site capacity of at least 28 ICATT testing appointments per day for observed specimen collection on-site or at least 20 unobserved, self-sample collection kit pick-ups,
  - v. At sites where appointments are not offered, during regular operations, the Contractor shall be prepared to meet a site capacity of at least 28 ICATT tests per day for observed specimen collection on-site or at least 20 unobserved, self-sample collection kit pick-ups, and
  - vi. For pharmacy sites, testing hours shall coincide with pharmacy hours.
- B. The Contractor shall also have the capability to conduct testing for periods of shorter duration (e.g., a couple of weeks) at offsite locations such as parking lots, aggregate settings, and population dense areas within two weeks of request and in inclement weather (temperate rain, heat, cold, wind), but not severe conditions where Contractor would be required to enact emergency actions plans as required under 29 CFR 1910.38 (<https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.38>). Notwithstanding the foregoing, Contractor will be allowed to have longer than two weeks to establish temporary testing in an area in the event that Contractor is unable to establish temporary testing in such area due to acts beyond Contractor's reasonable control (including, but not limited to, acts of God, terrorist acts, civil unrest, war, or extreme weather or environmental events).
- C. The Contractor shall abide by all federal and state scope of practice laws, regulations, and policies.
- D. The Contractor shall provide inside and outside communications/signage indicating that HHS funds the no-cost testing program instructing patients how they should proceed to be tested.
- E. The Contractor shall provide inside and outside communications/signage indicating that HHS funds the nocost testing program instructing patients how they should proceed to be tested.
- F. Billing for Uninsured Individuals: For testing, the swab and send fee will include reimbursement for scheduling, registration, sample collection, sample transport, laboratory-based PCR testing, and results reporting. The swab and send fees shall only apply when the test taker presents with no valid insurance and insurance discovery is unsuccessful

**Vaccination Services Site Locations**

- A. The Contractor shall make reasonable efforts to offer Vaccination Services at **all** retail pharmacy locations where allowed by law, not just sites that are currently established for testing under this contract. Each location shall receive a unique Facility ID for payment and reporting purposes.
- B. The Contractor shall set up additional sites to broaden the number of locations where vaccines are available in low-access and low-vaccination coverage areas. Many of these sites may be operated in partnership with community organizations for example, in a place of worship or at a community center). Sites may be mobile, or set up for a few weeks, and sites that are operational for more than 5 days will be eligible for the low-access or low-vaccination coverage payments if in locations meeting those definitions. CDC will review and approve all sites and each physical location will obtain a unique Facility ID before operating.
- C. The Contractor shall also conduct vaccination services for periods of shorter duration (e.g., a couple of weeks) at offsite locations such as parking lots, aggregate settings, and population dense areas within two weeks of request by the Government and in inclement weather (temperate rain, heat, cold, wind), but not severe conditions where Contractor would be required to enact emergency actions plans as required under 29 CFR 1910.38 (<https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.38>). Each off-site location should obtain a unique Facility ID and CDC consent before operating.
- D. The Contractor shall abide by all federal and state scope of practice laws, regulations, and policies.
- E. The Contractor shall provide communications indicating that HHS funds the no-cost vaccination program instructing patients how they should proceed.
- F. Contractor shall use reasonable efforts to ensure that service sites where vaccines are available are open for 8 hours per day, from 9:00 a.m. to 5:00 p.m. Notwithstanding the foregoing, Contractor shall, in its sole discretion, have the ability to adjust the operating times for when service sites offer vaccines as necessary in order to provide vaccine service sites during non-working hours.

**4.) Site Selection and Other Requirements:**

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Site Locations unless otherwise stated.*

- A. The Government must approve Contractor-recommended Services site locations and hours of operation before the Contractor begins work testing to ensure appropriate distribution and prevent duplication with other Contractors. The Government will review Contractor-recommended site locations and hours within seven days of submitting recommended sites within HHS Protect for review and approval. Surge sites may also be identified or recommended by state and federal government in consultation and coordination with the Contractor
- B. The Contractor shall use the Facility ID #, as provided by HHS Protect for each Services site location, when reporting in HHS Protect or through the state IIS.
- C. Contractor shall report new Services sites and site updates in accordance with Attachment J.1, section D.
- D. The Contractor shall notify the government and provide a list of sites that are added or no longer providing Services each week via email or other electronic reporting system as agreed between the Contractor and Government.
- E. The Contractor shall ensure that HHS Protect records Services statuses, site locations, site number, site metadata, and ICATT participation status correctly with the Government monthly as described in Attachment J.1, Section F. All status changes are reported to HHS Protect, COR, and the project manager.
- F. The Contractor shall notify the Government seven calendar (7) days in advance before closing a site.
- G. The Contractor shall update their Services sites with Castlight Health and Google and vaccine sites on [www.vaccines.gov](http://www.vaccines.gov) on a biweekly basis with additions and closures as appropriate to ensure the public can locate Services sites.

## 5.) Patient Registration and Consent

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Site Locations unless otherwise stated.*

- i. The Contractor shall provide an online platform which is smartphone compatible where patients can perform initial registration. The website shall be section 508 compliant. The website shall provide:
  - a. Clear step by step description of the Services testing process. Each step shall be described using clear and simple language that a member of the general public would be able to understand.
  - b. Align with CDC national Services priorities: <https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html>
  - c. Refer patients to CDC Services guidance
  - d. Clear eligibility criteria
  - e. Detailed guidance on no-cost testing
  - f. Acknowledgement of HHS funding support
  - g. A site map appointment availability, and operating hours for each testing location
  - h. Answers to frequently asked questions about Services (developed and maintained by the Contractor)
  - i. Type of Services available at each location
  - j. How and when results will be returned
  - k. Requirements for testing children
  - l. Toll free point of contact for additional information
  - m. Explanation if a pharmacy rejects Services testing according to CDC guidance
  - n. Whether a doctor's referral is necessary for patient receipt of Services
- ii. Through the registration process or at the testing site, the Contractor shall request patient information through a screening process compliant with Attachment J.1, Exhibit A in Attachment J.1, and an informed consent for Services.
- iii. The Contractor shall implement screening criteria as provided by the Government (see Exhibit A in Attachment J.1, for current screening questions). The Contractor shall adopt a screening protocol that is consistent with the CDC priorities and guidelines for COVID-19 Services. The Government may change the criteria for Services provision; however, the Contractor shall have a reasonable amount of time to design, test, and implement new or revised screening questions in electronic interface used by the Contractor. The Contractor shall obtain approval from the Government to change any criteria. CDC publishes priorities for COVID-19 Services. This guidance can change periodically. It is the Contractor's responsibility to check the CDC website periodically for updates.
- iv. If the screening criteria are met, the Contractor shall arrange for a licensed healthcare practitioner to review and order the test. The Contractor shall have an integrated system for collecting information, tracking specimens, and reporting Services results. The Contractor may offer a standing order for Services if it complies with all federal and state laws and regulations.
- v. The Contractor shall be capable of uploading a group of test takers from a digital list when testing in congregate settings.
- vi. The Contractor's registration process shall be available and efficient for walk-up test takers.
- vii. In addition to an electronic registration process, the Contractor shall provide for a paper registration process to allow for Services in environments where the electronic registration process would be less expedient than a paper registration process (e.g., registration of foreign nationals for whom the electronic registration process in English may present a barrier). The Contractor is responsible for subsequently capturing paper registrations in their electronic system.
- viii. The Contractor shall provide clear website communications that publicize the availability of no cost Services for uninsured and underinsured individuals. All materials should be shared with HHS for review and acknowledge HHS as the funder. The Contractor shall indicate on any communications delivered under this Program that the CDC Bridge Program is funded by HHS/CDC. Contractor shall provide information to patients about how patients may determine whether they are eligible for no-cost vaccination through the ICATT program

**6.) Site Preparation**

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Site Locations unless otherwise stated.*

- A. The Contractor may coordinate or enter into an agreement with state and local governments to supply items necessary to fulfill Services site needs, including supportive infrastructure.
- B. When providing full-service Services sites, the Contractor shall have prepared all necessary equipment (e.g., swabs, personal protective equipment (PPE), traffic flow management, and tents) prior to test takers' arrivals.
- C. For all new locations or sites where Services have not been performed for over one (1) week, the Contractor shall undergo a dry run where a small number of patients or the staff practice receiving Services, prior to operating at full capacity. Any site preparation or Services performance issues not resolved during the dry run shall be communicated to the Government by the end of the business day.
- D. Sites shall have the ability to properly store and monitor the storage of Services supplies to assure quality.

**7.) Patient Verification**

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Site Locations unless otherwise stated.*

- i. The Contractor shall be responsible for matching patients that arrive to the Services location to the correct laboratory requisition documentation. After verification, Contractor staff shall record the FDA EUA authorized or fully approved testing kit, vaccine lot number that is appropriately linked to the patient.
- ii. The Contractor shall implement processes that allow for sample tracking and transfer of sample collection kits to the laboratories (if required) while preventing or severely limiting, to the extent practicable, direct interaction between the Contractor's staff, or Contractor's subcontractors, partners, or vendor's staff (if applicable), and the patient.

**8.) Patient Testing (Testing Services)**

- A. When self-swab specimen collection is not be feasible, the Contractor shall collect the testing specimen via nasopharyngeal or via other swab administered by Contractor staff.
- B. The patient/test taker will be responsible for conducting self-swab testing. The Contractor shall ensure specimen collection is done in accordance with relevant CLIA regulations, FDA EUA, and manufacturer instructions. If the patient cannot perform a self-swab, the Contractor shall ensure that a member of Contractor staff perform the swabbing procedure in accordance with CLIA and manufacturer instructions. Contractor may include a telehealth option for specimen collection observation.
- C. The Contractor shall ensure all tests are performed according to FDA and CMS regulations, guidelines, and Frequently-Asked-Questions available from the CDC, FDA, and CMS websites.
- D. The Contractor shall maintain a safe distance between Contractor testing staff and patients as per CDC guidance. In the event a safe distance cannot be maintained, the Contractor shall ensure that contractor personnel are equipped with the necessary PPE to safely perform testing.
- E. The Contractor shall provide a location for patients to deposit self-collected specimens that meets the test manufacturer's specimen storage criteria and is in accordance with federal and state regulations.
- F. The Contractor shall provide the following test methods, as appropriate to the testing site, as proposed by the Contractor and approved by the Government at the point of site registration in HHS Protect; in limited circumstances the Government will provide OTC tests. While many tests listed below are optional to propose, the Contractor is encouraged to apply a broad mix of tests and sites to ensure resource and test manufacturing limitations do not impact contract performance.
  - a. Swab and send (Laboratory-based NAAT) testing

- i. The Contractor shall provide specimen collection kits at agreed-upon testing sites for the patient or Contractor to perform sample collection, and then the Contractor shall send the specimen to a laboratory for NAAT testing.
    - ii. Self-collection kits may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government. Contractor shall include pricing structure for test administration when the test kit is provided by the Government
  - b. Unobserved self-sample collection & laboratory-based NAAT testing
    - i. The Contractor shall provide self-collection kits for the patient to pick-up at agreed-up on sites or receive by mail, and then the patient returns the specimen to specified drop-off locations or mails it directly to a laboratory for testing. If returned to designated drop-off location, the Contractor shall send the specimen to a laboratory for NAAT testing.
    - ii. Self-collection kits may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government. Contractor shall include pricing structure for test administration when the test kit is provided by the Government
  - c. Point-of-Care (POC) NAAT testing
    - i. The Contractor shall provide POC NAAT testing at agreed-upon testing sites.
    - ii. Test kits may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government based on response needs and market conditions. Contractor shall include pricing structure for test administration when the test kit is provided by the Government
  - d. Point-of-Care (POC) Antigen testing
    - i. The Contractor shall provide POC testing at agreed-upon testing sites.
    - ii. Test kits may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government based on response needs and market conditions. Contractor shall include pricing structure for test administration when the test kit is provided by the Government.
  - e. Confirmatory POC testing
    - i. The Contractor shall provide POC testing at agreed-upon testing sites where antigen tests are used. For instance, if the Contractor supports Federally Supported Testing (optional to propose), then confirmatory POC testing is mandatory to offer.
    - ii. Test kits may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government based on response needs and market conditions. Contractor shall include pricing structure for test administration when the test kit is provided by the Government.
    - iii. Confirmatory testing is performed in specific settings, i.e., Federally Supported Testing, to confirm the result of a POC test to expedite patient management and processing.
  - f. Genomic Sequencing
    - i. As a function of public health activities in response to changing dynamics of the COVID-19 pandemic response (e.g., surveillance of The Contractor shall reflex a subset of samples for next generation sequencing for diagnostic purposes conducted under CLIA or other laboratory quality management systems. Sequencing shall be completed and data reported within one (1) week of request from the Government.
    - ii. Samples may come from sites at which the Contractor currently obtains specimens from its pharmacy-based testing and surge testing sites as well as from other third-party state testing sites as designated by the HHS and agreed on

- by the parties.
- iii. The Contractor shall provide:
    - 1. Data and metadata management
    - 2. Secured delivery of genomic data to local, state, or federal partners
    - 3. The uploading of genomic data and associated metadata (provided in bulk upload format by the sample submitter) to GenBank, according to CDC's minimum data requirements from the Genomic Sequencing Laboratory.
  - iv. Upon request, the Contractor shall ship a subset of samples to a designated state or federal public health laboratory within 48 hours of request for further testing.
  - v. The Contractor shall provide accessioning services for samples submitted directly by surveillance partners. Sample submitters are responsible for providing metadata to the testing laboratory in a bulk upload format.
- g. Multiplexed Testing
- i. Contractor may arrange for Multiplexed Testing for specimens that Contractor would otherwise already collect for purposes of COVID-19 testing, to test such specimens for both COVID-19 and Influenza (Type A and Type B). Contractor and the Government will mutually agree multiplexed Testing Locations.

**9.) Specimen Security/Preparation, Storage, Shipping, and Testing (Testing Services)**

- A. After the patient has deposited the used test kit in the collection area, the Contractor shall ensure that test kits are placed in appropriate storage and stored until processing in accordance with manufacturer instructions.
- B. The Contractor shall be responsible for ensuring all collected samples are tested in compliance with Center for Medicare and Medicaid Services' (CMS) Clinical Laboratory Improvement Amendments (CLIA). Consistent with the site selection and approval process identified in section 4.4.A, above, review of approval request shall occur with seven days of request submission.
- C. If testing is done at an off-site commercial lab subcontractor, the Contractor shall abide by all shipping and handling guidance when shipping specimens to its commercial lab subcontractor. The Contractor is responsible for all contracts, relationships, and payment with commercial lab subcontractors.

**10.) Notification of Results (Testing Services)**

- A. The Contractor shall make reasonable efforts to make test results available to test takers within 2 days after sample collection. Reasonable efforts are considered returning greater than 85% of total results per week (Monday through Sunday) within 2 days, ordering surge situations, where national percent positivity exceeds 10%, no more than 20% of test results being returned after 2 days or longer. Results made available to the test takers 3 days or longer after sample collection will be reimbursed at the government's discretion, if more than 20% of the total results for any given week exceed the 2-day deadline for more than 2 consecutive weeks. Prior to enacting discretion for reimbursement, the contractor shall have three weeks after notification by the government to make corrective actions such that no more than 10% of total results per week are made available 2 days or longer after sample collection. Upon notification from the Contractor that corrective action involves a change in laboratory partners, the Contractor and Government shall mutually agree upon a resolution period. The federal government will not execute reimbursement discretion, but may enact the option to request an improvement plan, if the contractor's one week turnaround time lies within one standard deviation of the mean ICATT program turnaround time (program average will be calculated by excluding the contractor turnaround time).
  - a. Test results should be communicated to test takers (or their legal guardians) either at the site, or in a manner approved by the relevant STLT Departments of Health.
  - b. Test results should be in writing: a handout provided at the testing site, email, text, or through the registration portal/application are acceptable. Phone calls are acceptable to provide results immediately but shall be followed up in writing.

- B. As described in section 4.15, the Contractor shall link any patient with a positive test result to relevant information about COVID-19 therapeutics. The Contractor shall link any individual with a negative test result to relevant information about COVID-19 vaccination. The Contractor shall regularly update therapeutics and vaccination information in their test results.
- C. The Contractor must comply with all state and local laws regarding reportable conditions, including but not limited to reporting to the relevant public health authorities with all data elements required by jurisdiction for submission of reportable results. The contractor shall ensure this compliance flows down to all subcontractors.

## 11.) Surge Site Infrastructure Management

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Surge Site Locations unless otherwise stated*

- A. The Contractor shall be equipped to provide site management in the event that surge site partners (such as state, local governments, or federal agencies) are not able to provide these services. The Government will identify surge sites and provide surge site testing authorization based on ICATT program needs.
- B. A mutual agreement between Contractor and the Government as to whether surge site infrastructure management is needed shall be made on a site-by-site basis. Federal and state partners will remain responsible for State/Federal Government Responsibilities in Section 4.12.vi
- C. Contractor surge site management responsibilities include:
  - i. Biohazardous waste management and disposal (e.g., gloves, masks)
  - ii. Physical management of the site to include:
    - 1. Site interaction with site point of contact for all logistics coordination
    - 2. Clinical staffing; traffic control within site; managerial staffing
    - 3. Nonmedical equipment including tents, cones, tables, chairs, electric power, generator, heaters, porta potty (if restroom unavailable)
    - 4. Storage of specimens in accordance with manufacturer instructions
    - 5. Unless the number of daily testing participants is anticipated to be more than two hundred fifty (250), an unarmed security guard who can contact local police and deescalate low level security concerns when conditions warrant security presence and/or at the recommendation of the local jurisdiction.
  - iii. Provision of laptops; printers; supplies for printing
  - iv. Subject Matter Expert (SME) on technology platform for registration, technology, and troubleshooting
  - v. Office supplies including Sharpies, pens, paper
  - vi. Wi-Fi access hot spots
  - vii. Printed informational materials (as needed)
  - viii. Managing storage; inventory/reporting and redistribution of supplies (laptops, test kits, PPE) from storage location to sites when required
  - ix. Coordination of returning unused supplies at the end of surge site events
  - x. Assignment of a POC per site for shipping or courier service driver/dispatch to contact upon arrival
  - xi. Daily delivery of specimens to an appropriate shipping or courier drop-off location when a site is not at a physical street address (e.g., a park and ride) or in rural areas that do not have regular pickup service.
  - xii. Staffing for registration/check-in for onsite patient registration and line management
  - xiii. Designated clinical staff assigned to be on point for medical emergencies
  - xiv. On-site advertising of the event
- D. Surge sites established in the US Affiliated Pacific Islands and Territories may incur additional management fees due to increased logistical challenges with sample processing.

## 12.) Federally Supported Testing (Testing Services)

- i. The Contractor shall perform POC or equivalent using an authorized diagnostic test at agreed-

- upon federally supported locations.
- ii. POC tests may be provided by the Contractor, test site partner, state/local government, or the federal government. The source of test will be decided at the sole discretion of the Government. Contractor shall include pricing structure for test administration when the test kit is provided by the Government. If the test provided by the government requires additional testing platform equipment (e.g., readers), the Government will supply this equipment as government-furnished property; the list of equipment will need to be confirmed as necessary by the government prior to procuring it.
  - iii. The Contractor shall perform confirmatory POC testing to confirm rapid POC-positive tests in all people and negative tests in symptomatic people. The Contractor shall follow any other CDC recommendations for confirmation of POC tests (<https://www.cdc.gov/coronavirus/2019-ncov/lab/>). Confirmatory POC tests can be purchased by the Contractor or provided by the government; the source of the confirmatory test will be decided at the sole discretion of the government. If provided by the government, [redacted] will be subtracted from the cost of this provision of testing. Requirements for Confirmatory testing in this high-density setting are:
    - a. Rapid time to results (<30 minutes)
    - b. Portable handheld instrument/reader/device that can be taken to the patient, rather than transport of specimen or patient to other testing location, appropriate for use as confirmatory test (no presumptive results).
  - iv. The Contractor shall provide availability of staff and necessary equipment to conduct 24 hour, 7 days a week testing at agreed-upon federally supported locations. In the event the government is unable to provide a fixed structure where the testing will be performed, the Contractor shall provide an appropriate facility or unit for testing that is cost-beneficial to the government. Staff will be on call for screening testing at all hours and capable of testing at least 100 people per hour within one (1) hour of notification.
  - v. Specimens shall not be shipped; test results shall be available rapidly to make the quarantine decisions promptly. Tasks described in section 4.11.C will be included in the cost of Federally Supported Testing.
  - vi. State/Federal Government Responsibilities:
    - a. Selection and coordination of site POC for logistics coordination of site locations; including any necessary permits
    - b. Biohazardous waste management and disposal (e.g., gloves, masks)
    - c. Media relations
    - d. Identification of state and local POCs
    - e. Testing hours/days
    - f. Go live/closing dates
    - g. Identification of number of tests to be performed in total
    - h. Storage location for supplies
  - vii. The government will provide four (4) weeks notice for expansion, contraction, or transition of services of federally supported locations.

(b)(4)

### 13.) Drive Through-Independent Testing Approaches (Testing Services)

- A. The Contractor shall provide at least one testing approach independent of the need for a drive-through that can be implemented at pharmacy sites. These testing models may include testing in pharmacy parking lots or offsite locations and/or unobserved, self-sample collection and testing, as described below.
- B. Parking Lot and Offsite Testing
  - i. The model will allow for testing of at least 100 people per day, whether walk up or drive up. Appropriate signage shall be displayed to promote and direct testing.
  - ii. The site shall offer reasonable protection from weather so that the site can be operated year-round, including in inclement weather (reference section 4.3.C).
  - iii. The contractor shall be able to move testing sites within two weeks' notice to mutually agreed upon locations.
  - iv. Testing can be POC, laboratory based, or other suitable method and the testing fee should reflect the testing method. The contractor shall also develop the capability to conduct



testing at offsite non-pharmacy locations, which may include non-parking lot sites, such as a stadium infield, school gymnasium, community center, or green space.

- C. Unobserved, Self-Sample Collection and Drop-Off
  - i. To improve the efficiency of COVID-19 testing and offer options to those who cannot be tested in a traditional setting (i.e., drive through testing), the Contractor shall provide a self-collection kit that can be performed at home or other location.
    - 1. At locations where remote sample drop-off occurs, Contractor shall ensure a capacity of at least 30 samples per day, per sample drop-off location.
  - ii. The patient is responsible for returning completed sample collection kits to drop off locations for testing, such as pharmacies drop boxes or smart lockers, for pick up and testing by the Contractor.
  - iii. At drop-off sites, the Contractor shall continue to be responsible for the same specific tasks and technical requirements as outlined for other testing sites (reference sections 4.1.) – 4.C).
  - iv. Contractor shall ensure that all unobserved, self-sample collection and testing signage and other promotional paraphernalia clearly acknowledge HHS funding support.

#### 14.) Submission of Specimens of Interest for Further Characterization (Testing Services)

- i. The Contractor shall submit specific specimens for further characterization (e.g., genomic sequencing) to state or federal laboratories as identified by the Government.
- ii. The Contractor shall work with the testing laboratory to identify, aliquot and provide the necessary metadata to be shipped with each sample to the state or federal facility in accordance with International Air Transport Association (IATA), state, and federal guidelines.

#### 15.) Combined Testing/Wraparound Services

- A. The Contractor shall connect any patient who receives a positive or indeterminate COVID-19 test result with appropriate information on how to receive such therapeutics at the testing location or other Services Site. In addition, the Contractor shall link any individual with a negative test result to relevant information about COVID-19 vaccination and how to receive such therapeutics at the testing location or other Services Site. The Contractor shall regularly update therapeutics and vaccination information in their test results.
- B. At pharmacy sites where COVID-19 vaccinations are available, the Contractor shall provide information on how to schedule a vaccination appointment or, if available, offer a walk-up vaccination to any patient who receives a negative COVID-19 test result and who has not already been fully vaccinated against SARS CoV-2. Opportunity to receive a vaccination shall be offered at time of negative result notification to the patient.
- C. Contractor shall include linkage to the HHS Programs.
  - a. To further the missions of the HHS programs and CDC ICATT programs, ICATT patients that receive testing services will be provided links to patient recruitment information. Outreach to ICATT patients may include links to the HHS program on the Contractor's website and in test result report, provision of study information, and in-person engagement with patients.
  - b. The Contractor shall provide any of three outreach methods (Digital/Informational Templates/In Person Engagement). At Contractor's discretion, Contractor may choose to participate in any one or a combination of the three outreach methods depending on location. Fees for digital services should be a one-time fee and fees for making Contractor-specific information available and in person patient engagement should be per location per month. Services offered in a partial month shall be prorated.
    - i. DIGITAL  
The Contractor shall provide electronic links and brief information about the program on one or more of the systems generated testing voucher, the appointment scheduled email, the results ready email, or the results report. Information may include written text and visual images and will include website links, phone numbers, and other necessary contact information. All necessary information about the program will be provided to the Contractor by the federal government to ensure this task is performed. Program links and information will be aligned with the test recipient's testing site to ensure only test recipients at a testing

site within a specific distance or drive time from the study sites will have access to information about the program, regardless of test recipient's test result. The zip code alignment and strategy will be mutually agreed upon by the Contractor and the government. Phone numbers for specific study sites will be visible on the Contractor website depending on the location of the test recipient. Study site testing locations and distance and drive time information will be provided by the government. The Contractor will provide mutually agreed upon digital metrics, i.e., key performance indicators, for the effectiveness of websites and digital test reports so that minor modifications can be made dynamically to optimize the process. Digital metrics will be calculated using the number of registered study participants over the number of tests performed from data provided by HHS programs. If provided, DIGITAL services shall be implemented within eight (8) weeks of the execution of the applicable contract modification.

ii. **INFORMATIONAL MATERIALS**

The Contractor shall make available Contractor-specific information, including, but not limited to QR code, website link, phone number, other contact information as well as basic program information. The federal government will provide content related to the program, communication assets, and key messages that can be leveraged for Contractor-specific channels. The form, content, size, quantity, and quality of communication materials will be jointly agreed upon by the Contractor and government once the contract between both has been finalized. Fees for materials will be the responsibility of the Contractor. If provided, Informational Materials services shall be implemented within eight (8) weeks of execution of the applicable contract modification.

iii. **IN-PERSON ENGAGEMENT**

The Contractor shall engage test takers such as after sample collection, to inform them of the program. This information should be made available both digitally and physically by the Contractor. The federal government shall provide key messages for use in developing a script that takes no longer than one minute to communicate to test takers. If provided, In-Person Engagement services shall be implemented within eight (8) weeks of execution of the applicable contract modification.

## **16.) Support Services**

*The following is applicable to Testing and Vaccination Services (collectively, "Services") Site Locations unless otherwise stated.*

- A. For patients who may require assistance (including non-English speakers; adults aged 65 years and older; children below the age of five; individuals with physical, learning, and/or cognitive disabilities; and individuals who are blind and/or deaf), the Contractor shall provide reasonable assistance to perform Services evaluation, maintain a reasonable speed of Services administration, and transitioning patients to and from the Services areas. Reasonable assistance includes foreign or sign language interpretation; support services for the blind and visually impaired; ambulatory support (e.g., wheelchairs); physical assistance; and support for individuals requiring assistance reading and/or understanding directions.

## **17.) Additional Services Line Item**

- A. Given the uncertainty of changing Services needs, the Government may elect to exercise a contract line-item option of varying percentages of the base task to support additional Services as specified in Section B.
- B. In addition, the Government may elect to exercise a separate optional line item for Additional Vaccination Services for the administration of additional doses of COVID-19 vaccines from October 01, 2024, to December 31, 2024.

## **18.) Vaccination Services:**

- A. **Vaccination Services:**

- a. The Contractor shall be responsible for Vaccination Services as follows:
  - i. The procurement and storage of COVID-19 vaccinations, which shall be procured by Contractor through external agreements with the manufacturers set up as part of the HHS/CDC Bridge Access Program.
  - ii. The administration of COVID-19 vaccinations, including booster doses, to uninsured and underinsured persons.
  - iii. The Contractor shall not charge any cost-sharing to uninsured and underinsured patients or seek reimbursement from either the government or the vaccine manufacturer (through a Patient Assistance Program or use of donated vaccine).

**B. General Requirements:**

- a. The Contractor shall hire, or contract with, and retain necessary staff and licenses to perform all contracted functions;
- b. The Contractor shall procure, as specified, and ensure all necessary space, equipment, and storage is available for safe and secure administration and storage COVID-19 vaccines;
- c. The Contractor shall conduct community outreach directed at the uninsured and underinsured population, including marketing/advertising, events, partnerships with community-based organizations that serve uninsured and underinsured populations, etc.
- d. The Contractor shall participate in regular coordination calls with CDC staff and other funded pharmacies, health centers, and health departments to coordinate delivery of vaccinations to meet the needs of areas with high numbers of uninsured and underinsured populations, low vaccination rates, or low access to vaccination services
- e. The Contractor shall leverage data and technical assistance, made available by CDC, to determine the locations that the uninsured, underinsured, and unvaccinated populations, as well as to understand features and demographics of selected low-access and low-vaccinated areas, and better target outreach
- f. The Contractor shall track and monitor the results of outreach for required monthly reporting to CDC and to improve impact over time.
- g. The Contractor shall conduct the Insurance Discovery process to ensure patients receiving no-cost-to-the-patient vaccinations under this program are eligible.
- h. The Contractor shall report to CDC monthly and discuss during regular check-ins with CDC staff:
  - i. Number of vaccine doses that are billed to this channel. Note that CDC may audit this documentation if the ratio of vaccines dispensed under this mechanism significantly exceeds uninsured rate in the community
  - ii. A summary of all outreach conducted, including elements described in J.1.c.
  - iii. Other data elements to be reported, such as patient screening and demographic data, and site location data, are included in Attachment J.1.b and will be reported daily.

**SECTION 5 – GOVERNMENT FURNISHED MATERIALS**

To the extent applicable to the Services methodology utilized, the Government may, at its discretion:

1. Give access to playbooks, SOPs, one-pagers, and other informational resources.
2. Assist with sourcing (but not procuring) nasal swab test kits needed to operate the self-swab testing sites.
3. Assist with communicating to state and local Departments of Health where private sector partners (e.g., retailers, pharmacies, clinics) would like to operate these sites.
4. Assist by providing data and guidance on which counties, states, and regions to place self- swab sites.
5. Assist by providing data and technical assistance on where uninsured and underinsured people live and the locations if low-access and low-vaccination coverage areas, as well as to help understand features and demographics of selected low-access and low-vaccinated areas
6. Provide testing materials (e.g., test kits, PPE) when pandemic response needs and market conditions require government provision in order ensure expedient and safe ICATT testing availability.
7. Give access to HHS Protect and state IIS systems for reporting purposes.
8. Training to HHS Protect and use of state IIS systems, as needed.

**SECTION 6 – PERIOD OF PERFORMANCE**

See Section B.

**SECTION 7 – DELIVERABLES/REPORTING SCHEDULE**

| Item #      | SOW Reference  | Deliverable Description  | Date of Delivery   |
|-------------|--|--|--|
| 1.a and 1.b | See: Section 4 and Attachment J.1.a. and J.1.b, Sections A – C | Daily Services Reports, including Patient Screening and Demographics and Services Encounter Data                       | Daily  |
| 1.c         | Section 4 and Attachment                                       | Outreach Summary Data  | Monthly  |
| 2           | See: Section 4 and Attachment J.1, Section D                   | Services Site Data   | As Need, Prior to Site Launch                                  |
| 3           | See: Attachment J.1, Section                                   | Over-the-Counter COVID-19 Test Sales   | Weekly   |
| 4           | See: Section 4 and Attachment J.1, Section F                   | Testing Site Metadata  | Prior to Site Launch and at Least Monthly                      |
| 5           | See: Section 4   | Site Updates with Google for testing and <a href="http://www.vaccines.gov">www.vaccines.gov</a> for vaccines           | At least biweekly  |
| 6           | See Section 4 and J.1.b  | Vaccination Monthly Report, includes monthly sales by payor (private insurance, Medicaid, Medicare, and cash payments) | Monthly (Unless otherwise agreed upon by the Government)       |
| 7.a         | Section 4  | Final Report Testing   | Within 30 days preceding the end of the Period of Performance. |
| 7.b         | Section 4  | Final Report Vaccinations  | Within 30 days preceding the end of the Period of Performance. |

**SECTION 8 – ICATT Vulnerable Population Testing, Reimbursement Shift to Private or Public Insurance Payments, Low-Access Population Payment, and Low-Vaccination Coverage Payment**

**Vulnerable Population Testing:** To achieve program goals, the Contractor will have an opportunity to receive a separate firm fixed price payment for exceeding testing goals in pharmacy and community testing sites only. The Contractor shall provide a plan detailing how they will achieve this goal. At the end of each calendar month, tests performed above the 60% non-white or Hispanic population goal will be paid a higher rate of payment. For instance, if 63% of total tests were reported in non-white or Hispanic populations, the contract would receive the base price per test and an extra (b)(4) for 3% of tests for that calendar month. This applies to any combination of tests provided or conducted at all locations in pharmacy and community testing sites only. The sum of the payments will not exceed (b)(4) per calendar month.

**Low-Access Population Payment:** To achieve program goals, the Contractor shall have an opportunity to receive separate, firm fixed price payments for vaccinations performed or therapeutics dispensed in census tracts that meet the definition of “low access”. The contractor should propose a monthly ceiling for low-access population payments in their business proposal.

- One payment will be ar (b)(4), until December 31, 2023, and (b)(4) from January 1, 2024, per vaccination administered. The contactor can invoice monthly as vaccines are administered.
- The second payment will be a one-time payment of (b)(4) until December 1, 2023, and (b)(4) from January 1, 2024, per site established in a low-access area. Sites will need to be in use for at least 5 days to receive payment. The contactor can invoice monthly as new sites are established.

3. Only sites approved by CDC are eligible for incentive payments.

**Low-Vaccination Coverage Payments:** To achieve program goals, the Contractor shall have an opportunity to receive separate, firm fixed price payments for vaccinations performed in census tracts that meet the definition of a “low-vaccination area”. The contractor should propose a monthly ceiling for low-vaccination coverage payments in their business proposal.

(b)(4)

1. One payment will be an (b)(4) until December 31, 2023, and (b)(4) from January 1, 2024, per vaccination administered. The contractor can invoice monthly as vaccines are administered.
2. The second payment will be a one-time payment of (b)(4) until December 1, 2023, and (b)(4) from January 1, 2024, per site established in a low-vaccination coverage area. Sites will need to be in use for at least 5 days to receive payment. The contractor can invoice monthly as new sites are established.
3. Only sites approved by CDC are eligible for incentive payments.

Sites may only qualify for either the low-vaccination or low-coverage payments. This includes payments per new site set up and payments per dose administered.

As described in attachment J.1 and Section 4.18, CDC will **collect data on a regular basis** from the Contractors, participating in this program, to capture site locations, vaccination and therapeutics encounters, partnerships/outreach, and patient demographics.

1. CDC will use the data to **create lists of locations** that qualify for the low-access area and low-vaccination coverage payment and provide an updated version of the list to the pharmacies each month. Areas included on each list would continue to qualify for these payments for approximately 3 months after they are included on a list, even if removed from the following month’s list.

## SECTION 9 – SPECIAL CONSIDERATIONS

### A. Baseline Security Requirements

1) Applicability. The requirements herein apply whether the entire contract or order (hereafter “contract”), or portion thereof, includes either or both of the following:

a. Access (Physical or Logical) to Government Information: A Contractor (and/or any subcontractor) employee will have or will be given the ability to have, routine physical (entry) or logical (electronic) access to government information.

b. Operate a Federal System Containing Information: A Contractor (and/or any subcontractor) employee will operate a federal system and information technology containing data that supports the HHS mission. In addition to the Federal Acquisition Regulation (FAR) Subpart 2.1 definition of “information technology” (IT), the term as used in this section includes computers, ancillary equipment (including imaging peripherals, input, output, and storage devices necessary for security and surveillance), peripheral equipment designed to be controlled by the central processing unit of a computer, software, firmware and similar procedures, services (including support services), and related resources.

2) Safeguarding Information and Information Systems. In accordance with the Federal Information Processing Standards Publication (FIPS)199, Standards for Security Categorization of Federal Information and Information Systems, the Contractor (and/or any subcontractor) shall:

a. Protect government information and information systems in order to ensure:

- Confidentiality, which means preserving authorized restrictions on access and disclosure, based on the security terms found in this contract, including means for protecting personal privacy and proprietary information;
- Integrity, which means guarding against improper information modification or destruction, and ensuring information non-repudiation and authenticity; and
- Availability, which means ensuring timely and reliable access to and use of information.

b. Provide security for any Contractor systems, and information contained therein, connected to an HHS network or operated by the Contractor on behalf of HHS regardless of location. In addition, if new or unanticipated threats or hazards are discovered by either the agency or contractor, or if existing safeguards have ceased to function, the discoverer shall immediately, within one (1) hour or less, bring the situation to the attention of the other party.

c. Adopt and implement the policies, procedures, controls, and standards required by the HHS Information Security Program to ensure the confidentiality, integrity, and availability of government information and government information systems for which the Contractor is responsible under this contract or to which the Contractor may otherwise have access under this contract. Obtain the HHS Information Security Program security requirements, outlined in the HHS Information Security and Privacy Policy (IS2P), by contacting the CO/COR or emailing [fisma@hhs.gov](mailto:fisma@hhs.gov).

d. Comply with the Privacy Act requirements and tailor FAR clauses as needed.

CDC Implementation of HHS Security and Privacy Language for Information and Information Technology Procurements Language, Version 1.0 Page 11

Office of the Chief Information Security Officer (OCISO)

3) Information Security Categorization. In accordance with FIPS 199 and National Institute of Standards and Technology (NIST) Special Publication (SP) 800-60, Volume II: Appendices to Guide for Mapping Types of Information and Information Systems to Security Categories, Appendix C, and based on information provided by the ISSO, CISO, or other security representative, the risk level for each Security Objective and the Overall Risk Level, which is the highest watermark of the three factors (Confidentiality, Integrity, and Availability) of the information or information system are the following:

| Information Type                                       | Confidentiality | Integrity | Availability |
|--|-----------------|-----------|--------------|
| C.2.8.9 Personal Identity and Authentication           | Moderate        | Moderate  | Moderate     |
| D.14.1 Access to Care Information                      | Moderate        | Moderate  | Low          |
| D14.2 Population Health Management and Consumer Safety | Moderate        | Moderate  | Low          |
| D.14.3 Health Care Administration                      | Moderate        | Moderate  | Low          |
| D.14.4 Health Care Delivery Services                   | Moderate        | Moderate  | Low          |
| <b>Overall Risk</b>                                    | Moderate        | Moderate  | Moderate     |

Based on information provided by the ISSO, Privacy Office, system/data owner, or other security or privacy representative, it has been determined that this solicitation/contract involves:

No PII  Yes PII

4) Personally Identifiable Information (PII). Per the Office of Management and Budget (OMB) Circular A-130, "PII is information that can be used to distinguish or trace an individual's identity, either alone or when combined with other information that is linked or linkable to a specific individual." Examples of PII include, but are not limited to the following: social security number, date and place of birth, mother's maiden name, biometric records, etc.

PII Confidentiality Impact Level has been determined to be:  Low  Moderate  High –Not applicable, system is not processing PII of any type.

5) Controlled Unclassified Information (CUI). CUI is defined as "information that laws, regulations, or Government-wide policies require to have safeguarding or dissemination controls, excluding classified information." The Contractor (and/or any subcontractor) must comply with Executive Order 13556, Controlled

Unclassified Information, (implemented at 32 CFR, part 2002) when handling CUI. 32 C.F.R. 2002.4(aa) As implemented the term “handling” refers to “...any use of CUI, including but not limited to marking, safeguarding, transporting, disseminating, re-using, and disposing of the information.” 81 Fed. Reg. 63323. All sensitive information that has been identified as CUI by a regulation or statute, handled by this solicitation/contract, shall be:

- a. marked appropriately;
- b. disclosed to authorized personnel on a Need-To-Know basis;
- c. protected in accordance with NIST SP 800-53, Security and Privacy Controls for Federal Information Systems and Organizations applicable baseline if handled by a Contractor system operated on behalf of the agency, or NIST SP 800-171, Protecting Controlled Unclassified Information in Nonfederal Information Systems and Organizations if handled by internal Contractor system; and
- d. returned to HHS control, destroyed when no longer needed, or held until otherwise directed.

CDC Implementation of HHS Security and Privacy Language for Information and Information Technology Procurements Language, Version 1.0 Page 12

Office of the Chief Information Security Officer (OCISO)

Destruction of information and/or data shall be accomplished in accordance with NIST SP 800-88, Guidelines for Media Sanitization.

6) Protection of Sensitive Information. For security purposes, information is or may be sensitive because it requires security to protect its confidentiality, integrity, and/or availability. The Contractor (and/or any subcontractor) shall protect all government information that is or may be sensitive in accordance with OMB Memorandum M-06-16, Protection of Sensitive Agency Information by securing it with a FIPS 140-2 validated solution.

7) Confidentiality and Nondisclosure of Information. Any information provided to the contractor (and/or any subcontractor) by HHS or collected by the contractor on behalf of HHS shall be used only for the purpose of carrying out the provisions of this contract and shall not be disclosed or made known in any manner to any persons except as may be necessary in the performance of the contract. The Contractor assumes responsibility for protection of the confidentiality of Government records and shall ensure that all work performed by its employees and subcontractors shall be under the supervision of the Contractor. Each Contractor employee or any of its subcontractors to whom any HHS records may be made available or disclosed shall be notified in writing by the Contractor that information disclosed to such employee or subcontractor can be used only for that purpose and to the extent authorized herein.

The confidentiality, integrity, and availability of such information shall be protected in accordance with HHS and [CDC] policies. Unauthorized disclosure of information will be subject to the HHS/[CDC] sanction policies and/or governed by the following laws and regulations:

- a. 18 U.S.C. 641 (Criminal Code: Public Money, Property or Records);
- b. 18 U.S.C. 1905 (Criminal Code: Disclosure of Confidential Information); and
- c. 44 U.S.C. Chapter 35, Subchapter I (Paperwork Reduction Act).

8) Internet Protocol Version 6 (IPv6). All procurements using Internet Protocol shall comply with OMB Memorandum M-05-22, Transition Planning for Internet Protocol Version 6 (IPv6) . .

9) Government Websites. All new and existing public-facing government websites must be securely configured with Hypertext Transfer Protocol Secure (HTTPS) using the most recent version of Transport Layer Security (TLS). In addition, HTTPS shall enable HTTP Strict Transport Security (HSTS) to instruct compliant browsers to assume HTTPS at all times to reduce the number of insecure redirects and protect against attacks that attempt

to downgrade connections to plain HTTP. For internal-facing websites, the HTTPS is not required, but it is highly recommended.

10) Contract Documentation. The Contractor shall use provided templates, policies, forms and other agency documents to comply with contract deliverables as appropriate.

Security baseline deliverables

| Document Section                        | Deliverable Title/Description                             | Due Date  |
|---|---|---|
| 2 – Rules of Behavior                   | Signed ROB for all employees accessing HHS Protect        | Initiation of contract and at least annually thereafter |
| 2 – Personnel Security Responsibilities | List of Personnel with defined roles and responsibilities | Prior to performing any work on behalf of HHS           |

11) Standard for Encryption. The Contractor (and/or any subcontractor) shall:

a. Comply with the HHS Standard for Encryption of Computing Devices and Information to prevent unauthorized access to government information.

b. Encrypt all sensitive federal data and information (i.e., PII, protected health information [PHI],

CDC Implementation of HHS Security and Privacy Language for Information and Information Technology Procurements Language, Version 1.0 Page 13 Office of the Chief Information Security Officer (OCISO) proprietary information, etc.) in transit (i.e., email, network connections, etc.) and at rest (i.e., servers, storage devices, mobile devices, backup media, etc.) with FIPS 140-2 validated encryption solution.

c. Secure all devices (i.e.: desktops, laptops, mobile devices, etc.) that store and process government information and ensure devices meet HHS and CDC-specific encryption standard requirements. Maintain a complete and current inventory of all laptop computers, desktop computers, and other mobile devices and portable media that store or process sensitive government information (including PII).

d. Verify that the encryption solutions in use have been validated under the Cryptographic Module Validation Program to confirm compliance with FIPS 140-2. The Contractor shall provide a written copy of the validation documentation to the COR.

e. Use the Key Management system on the HHS personal identification verification (PIV) card or establish and use a key recovery mechanism to ensure the ability for authorized personnel to encrypt/decrypt information and recover encryption keys.

12) Contractor Non-Disclosure Agreement (NDA). Each Contractor (and/or any subcontractor) employee having access to non-public government information under this contract shall complete the CDC non-disclosure agreement, as applicable. A copy of each signed and witnessed NDA shall be submitted to the Contracting Officer (CO) and/or CO Representative (COR) prior to performing any work under this acquisition.

13) Privacy Threshold Analysis (PTA)/Privacy Impact Assessment (PIA) – The Contractor shall assist the CDC Senior Official for Privacy (SOP) or designee with conducting a PTA for the information system and/or information handled under this contract in accordance with HHS policy and OMB M-03-22, Guidance for Implementing the Privacy Provisions of the E-Government Act of 2002.

a. The Contractor shall assist the CDC SOP or designee in reviewing the PIA at least every three years throughout the system development lifecycle (SDLC)/information lifecycle, or when determined by the CDC SOP that a review is required based on a major change to the system (e.g., new uses of information



collected, changes to the way information is shared or disclosed and for what purpose, or when new types of PII are collected that could introduce new or increased privacy risks), whichever comes first.

#### B. Training – Not Applicable to this Contract

1) Mandatory Training for All Contractor Staff. All Contractor (and/or any subcontractor) employees assigned to work on this contract shall complete the applicable HHS/CDC Contractor Information Security Awareness, Privacy, and Records Management training (provided upon contract award) before performing any work under this contract. Thereafter, the employees shall complete CDC Security Awareness Training (SAT), Privacy, and Records Management training at least annually, during the life of this contract. All provided training shall be compliant with HHS training policies.

2) Role-based Training. All Contractor (and/or any subcontractor) employees with significant security responsibilities (as determined by the program manager) must complete role-based training (RBT)

CDC Implementation of HHS Security and Privacy Language for Information and Information Technology Procurements Language, Version 1.0 Page 14 within 60 days of assuming their new responsibilities. Thereafter, they shall complete RBT at least annually in accordance with HHS policy and the HHS Role-Based Training (RBT) of Personnel with Significant Security Responsibilities Memorandum.

All HHS employees and contractors with SSR who have not completed the required training within the mandated timeframes shall have their user accounts disabled until they have met their RBT requirement.

3) Training Records. The Contractor (and/or any subcontractor) shall maintain training records for all its employees working under this contract in accordance with HHS policy. A copy of the training records shall be provided to the CO and/or COR within 30 days after contract award and annually thereafter or upon request.

#### C. Rules of Behavior

1) The Contractor (and/or any subcontractor) shall ensure that all employees performing on the contract comply with the HHS Information Technology General Rules of Behavior.

2) All Contractor employees performing on the contract must read and adhere to the Rules of Behavior before accessing Department data or other information, systems, and/or networks that store/process government information, initially at the beginning of the contract and at least annually thereafter, which may be done as part of annual CDC Security Awareness Training. If the training is provided by the contractor, the signed ROB must be provided as a separate deliverable to the CO and/or COR per defined timelines above.

#### D. Incident Response

FISMA defines an incident as “an occurrence that (1) actually or imminently jeopardizes, without lawful authority, the integrity, confidentiality, or availability of information or an information system; or (2) constitutes a violation or imminent threat of violation of law, security policies, security procedures, or acceptable use policies. The HHS Policy for IT Security and Privacy Incident Reporting and Response further defines incidents as events involving cybersecurity and privacy threats, such as viruses, malicious user activity, loss of, unauthorized disclosure or destruction of data, and so on.

A privacy breach is a type of incident and is defined by Federal Information Security Modernization Act (FISMA) as the loss of control, compromise, unauthorized disclosure, unauthorized acquisition, or any similar occurrence where (1) a person other than an authorized user accesses or potentially accesses personally identifiable information or (2) an authorized user accesses or potentially accesses personally identifiable information for an other than authorized purpose.

OMB Memorandum M-17-12, “Preparing for and Responding to a Breach of Personally Identifiable Information” (03 January 2017) states:

Definition of an Incident:

An occurrence that (1) actually or imminently jeopardizes, without lawful authority, the integrity, confidentiality, or availability of information or an information system; or (2) constitutes a violation or imminent threat of violation of law, security policies, security procedures, or acceptable use policies.

Definition of a Breach:

The loss of control, compromise, unauthorized disclosure, unauthorized acquisition, or any similar occurrence where (1) a person other than an authorized user accesses or potentially accesses personally identifiable information or (2) an authorized user accesses or potentially accesses personally identifiable information for an other than authorized purpose.

It further adds:

A breach is not limited to an occurrence where a person other than an authorized user potentially accesses PII by means of a network intrusion, a targeted attack that exploits website vulnerabilities, or an attack executed through an email message or attachment. A breach may also include the loss or theft of physical documents that include PII and portable electronic storage media that store PII, the inadvertent disclosure of PII on a public website, or an oral disclosure of PII to a person who is not authorized to receive that information. It may also include an authorized user accessing PII for an other than authorized purpose.

The HHS Policy for IT Security and Privacy Incident Reporting and Response further defines a breach as “a suspected or confirmed incident involving PII”.

Contracts with entities that collect, maintain, use, or operate Federal information or information systems on behalf of CDC shall include the following requirements:

- 1) The contractor shall cooperate with and exchange information with CDC officials, as deemed necessary by the CDC Breach Response Team, to report and manage a suspected or confirmed breach.
- 2) All contractors and subcontractors shall properly encrypt PII in accordance with OMB Circular A-130 and other applicable policies, including CDC-specific policies, and comply with HHS-specific policies for protecting PII. To this end, all contractors and subcontractors shall protect all sensitive information, including any PII created, stored, or transmitted in the performance of this contract so as to avoid a secondary sensitive information incident with FIPS 140-2 validated encryption.
- 3) All contractors and subcontractors shall participate in regular training on how to identify and report a breach.
- 4) All contractors and subcontractors shall report a suspected or confirmed breach in any medium as soon as possible and no later than 1 hour of discovery, consistent with applicable CDC IT acquisitions guidance, HHS/CDC and incident management policy, and United States Computer Emergency Readiness Team (US-CERT) notification guidelines. To this end, the Contractor (and/or any subcontractor) shall respond to all alerts/Indicators of Compromise (IOCs) provided by HHS Computer Security Incident Response Center (CSIRC) or CDC Computer Incident Response Team (CSIRT) within 24 hours via email at [csirt@cdc.gov](mailto:csirt@cdc.gov) or telephone at 866-655-2245, whether the response is positive or negative.
- 5) All contractors and subcontractors shall be able to determine what Federal information was or could have been accessed and by whom, construct a timeline of user activity, determine methods and techniques used to access Federal information, and identify the initial attack vector.
- 6) All contractors and subcontractors shall allow for an inspection, investigation, forensic analysis, and any other action necessary to ensure compliance with HHS/CDC Policy and the HHS/CDC Breach Response Plan and to assist with responding to a breach.
- 7) Cloud service providers shall use guidance provided in the FedRAMP Incident Communications Procedures when deciding when to report directly to US-CERT first or notify CDC first.
- 8) Identify roles and responsibilities, in accordance with HHS/CDC Breach Response Policy and the HHS/CDC Breach Response Plan. To this end, the Contractor shall NOT notify affected individuals unless and until so

instructed by the Contracting Officer or designated representative. If so instructed by the Contracting Officer or representative, all notifications must be pre-approved by the appropriate CDC officials, consistent with HHS/CDC Breach Response Plan, and the Contractor shall then send CDC- approved notifications to affected individuals; and,

9) Acknowledge that CDC will not interpret report of a breach, by itself, as conclusive evidence that the contractor or its subcontractor failed to provide adequate safeguards for PII.

#### E. Position Sensitivity Designations

All Contractor (and/or any subcontractor) employees must obtain a background investigation commensurate with their position sensitivity designation that complies with Parts 1400 and 731 of Title 5, Code of Federal Regulations (CFR).

| Investigation   | Position Requirement   |
|---|--|
| <input type="checkbox"/> NAC                              | National Agency Check  |
| <input type="checkbox"/> Tier 1                           | Low-Risk Non-Sensitive, including HSPD-12 Credentialing  |
| <input type="checkbox"/> Tier 2s (with subject interview) | Moderate-Risk Public Trust (MRPT)  |
| <input type="checkbox"/> Tier 3                           | Non-Critical Sensitive, National Security, including Secret and "L" access eligibility                             |
| <input type="checkbox"/> Tier 4                           | High-Risk Public Trust   |
| <input type="checkbox"/> Tier 5                           | Critical Sensitive and Special Sensitive, National Security, including Top Secret, SCI, and "Q" access eligibility |
| <input checked="" type="checkbox"/> Not Applicable        | No Requirement   |

#### F. Homeland Security Presidential Directive (HSPD)-12 – Not Applicable to this Contract

The Contractor (and/or any subcontractor) and its employees shall comply with Homeland Security Presidential Directive (HSPD)-12, Policy for a Common Identification Standard for Federal Employees and Contractors; OMB M-05-24; FIPS 201, Personal Identity Verification (PIV) of Federal Employees and Contractors; HHS HSPD-12 policy; and Executive Order 13467, Part 1 §1.2.

For additional information, see HSPD-12 policy at: <https://www.dhs.gov/homeland-security-presidential-directive-12>)

Roster. The Contractor (and/or any subcontractor) shall submit a roster by name, position, e-mail address, phone number and responsibility of all staff working under this acquisition where the Contractor will develop, have the ability to access, or host and/or maintain a government information system(s). The roster shall be submitted to the COR and/or CO by the effective date of this contract. Any revisions to the roster as a result of staffing changes shall be submitted immediately upon change. The COR will notify the Contractor of the appropriate level of investigation required for each staff member.

If the employee is filling a new position, the Contractor shall provide a position description and the Government will determine the appropriate suitability level.

#### G. Contract Initiation and Expiration – Not Applicable to this Contract

1) General Security Requirements. The Contractor (and/or any subcontractor) shall comply with information security and privacy requirements, Enterprise Performance Life Cycle (EPLC) processes, HHS Enterprise Architecture requirements to ensure information is appropriately protected from initiation to expiration of the contract. All information systems development or enhancement tasks supported by the contractor shall follow the HHS EPLC framework and methodology and in accordance with the HHS Contract Closeout Guide (2012).

HHS EA requirements may be located here: <https://www.hhs.gov/ocio/ea/documents/proplans.html>

CDC EPC Requirements: <https://www2a.CDC.gov/CDCup/library/other/eplc.htm>

- 2) System Documentation. Contractors (and/or any subcontractors) must follow and adhere to NIST SP 800-64, Security Considerations in the System Development Life Cycle, at a minimum, for system development and provide system documentation at designated intervals (specifically, at the expiration of the contract) within the EPLC that require artifact review and approval.
- 3) Sanitization of Government Files and Information. As part of contract closeout and at expiration of the contract, the Contractor (and/or any subcontractor) shall provide all required documentation to the CO and/or COR to certify that, at the government's direction, all electronic and paper records are appropriately disposed of and all devices and media are sanitized in accordance with NIST SP 800-88, Guidelines for Media Sanitization.
- 4) Notification. The Contractor (and/or any subcontractor) shall notify the CO and/or COR and system ISSO before an employee stops working under this contract.
- 5) Contractor Responsibilities Upon Physical Completion of the Contract. The contractor (and/or any subcontractors) shall return all government information and IT resources (i.e., government information in non-government-owned systems, media, and backup systems) acquired during the term of this contract to the CO and/or COR. Additionally, the Contractor shall provide a certification that all government information has been properly sanitized and purged from Contractor-owned systems, including backup systems and media used during contract performance, in accordance with HHS and/or CDC policies.
- 6) The Contractor (and/or any subcontractor) shall perform and document the actions identified in the CDC Out-Processing Checklist ([http://intranet.cdc.gov/od/hcrmo/pdfs/hr/Out\\_Processing\\_Checklist.pdf](http://intranet.cdc.gov/od/hcrmo/pdfs/hr/Out_Processing_Checklist.pdf)) when an employee terminates work under this contract. All documentation shall be made available to the CO and/or COR upon request.

#### H. Records Management and Retention

The Contractor (and/or any subcontractor) shall maintain all information in accordance with Executive Order 13556 -- Controlled Unclassified Information, National Archives and Records Administration (NARA) records retention policies and schedules and HHS policies and shall not dispose of any records unless authorized by HHS.

#### **Vaccinations Government Monitoring:**

- a. CDC may implement processes to ensure appropriate use of government funds on vaccinations only for the uninsured and under insured. Beyond the currently required patient insurance attestation, encounter data-level patient insurance status reporting, and insurance discovery processes, these may include periodic facility-level monitoring. For example:
  - i. Running weekly spot checks on facility-level data, comparing the number of vaccinations billed to the ICATT program for a particular site to the overall number of vaccinations provided by that site, and ensuring the ratio is not significantly dissimilar from the overall uninsured rate in that census tract.
  - ii. Using either planned site visits or a "secret shopper" technique or both to spot-check facilities to ensure they are asking patients to attest to insurance status as required and that backend processes meet program requirements.

## Section I-1 - Clauses Incorporated By Reference

*Add:*

| <b>FAR SOURCE</b> | <b>TITLE AND DATE</b>           |
|-------------------|---------------------------------|
| 52.245-1          | Government Property (Sept 2021) |

## **Section J – List of Attachments**

- Attachment J.1 – Testing Data Reporting Requirements
- Attachment J.1.b – Vaccination Data Reporting Requirements
- Attachment J.1.c. – Summary of Outreach Conducted for Bridge Access Program

**Attachment J.1 Vaccination: Data Elements for Vaccines (Bridge Program)**

Vaccination data enumerated in sections A through B below shall be reported daily to the HHS Protect system or other system designated by the Government. Site Data enumerated in section C shall be reported to the Government upon launch of a new site and then ongoing on a weekly basis.

CDC routinely collects patient demographic data to inform the equitable and efficient administration of our programs. The data will be uploaded and processed in a secured environment rate for PII. This data is being collected in compliance with 45C.F.R. part 46.102(l)(2), 21C.F.R. part 56; 42 U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq.

|  |
|--|
| Fields present in pre-existing J1 document |
| New fields required                        |

**A. Vaccination Related Fields**

| Field Name                    | Format     | Description/Options  | Example  | Vendor-Specific Notes |
|-------------------------------|------------|--|--|-----------------------|
| Vaccination Event ID          | String     | Unique identifier for each vaccination to prevent duplicate result submission                              | 578928889  |                       |
| Vaccination Administered Date | MM/DD/YYYY | The date the vaccination was administered  | 11/01/2021   |                       |
| Facility ID                   | String     | Unique identifier for each site. Contractor shall obtain approval from the Government for the Facility ID. | P2000  |                       |
| Vaccine manufacturer name     | String     | The manufacturer of the vaccine that was administered.   | Pfizer, Moderna, etc.  |                       |
| Vaccine product               | String     | NDC of product administered  | 80777-282-05   |                       |
| Vaccine product               | String     | CVX of product administered  | 519<br><a href="https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx">https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx</a> |                       |
| Copay                         | String     | Indicator whether copay applies  | Yes/No   |                       |

**B. Patient-Related fields**

| Field Name               | Format      | Description/Options                                  | Example | Vendor-Specific Notes |
|--------------------------|-------------|--|---------|-----------------------|
| Patient Residence County | County name | The county (not the city) where the patient resides. | Harris  |                       |

|                         |                             |   |                           |  |
|-------------------------|-----------------------------|---|---------------------------|--|
| Patient Zip Code        | ZIP                         | 5-digit ZIP code of patient residence   | 10000                     |  |
| Patient Residence State | 2-letter state abbreviation | The state where the patient resides.  | TX                        |  |
| Patient birth year      | YYYY                        | The birth year of the patient   | 1978                      |  |
| Patient Gender          | String                      | Male, Female, Other, Not Reported   | Female                    |  |
| Patient Race            | String                      | American Indian or Alaska Native; Asian; Black or African American; Native Hawaiian or Other Pacific Islander; White; Other; Not Reported | Black or African American |  |
| Patient Ethnicity       | String                      | Hispanic/Latino; Non-Hispanic/Latino; Not Reported  | Hispanic/Latino           |  |
| Patient ID              | String                      | Unique identifier for the patient, if available, subject to the condition that the identifier cannot be linked back to the patient        |                           |  |

**C. Vaccination Site Related Fields**

| Field Name       | Format                              | Description/Options  | Example       | Vendor-Specific Notes |
|------------------|-------------------------------------|--|---------------|-----------------------|
| Facility ID      | Defined by Contractor or Government | Unique identifier for each site. Contractor shall obtain approval from the Government for the Facility ID. | P2000         |                       |
| Site Description | String                              | Description of vaccination site to include relevant details at discretion of Government and Contractor.    | Store #10000  |                       |
| Address          | Address                             | Address of vaccination site  | 100 S Main St |                       |
| City             | City                                | City of vaccination site   | Houston       |                       |
| State            | Two-letter state abbreviation       | State of vaccination site  | AK            |                       |
| ZIP Code         | ZIP                                 | 5-digit ZIP code of  | 10000         |                       |



|              |            |  |  |  |
|--------------|------------|--|--|--|
|              |            | vaccination site   |  |  |
| Go Live Date | MM/DD/YYYY | Date site began vaccination.   | 11/01/2021                               |  |
| IIS ID       | String     | Identifier assigned by IIS to the Provider Organization  | State specific ID used for IIS reporting |  |
| Pharmacy NPI | String     | National Provider Identification number for the pharmacy (i.e. not the pharmacist or the prescriber) | 1528162450                               |  |

**J.1.c - Summary of Outreach Conducted for Bridge Access Program**

Due monthly as indicated in the SOW Section 4.18.C and deliverables table.

**A. Partnerships and Outreach Data**

| <b>Field Name</b>   | <b>Format</b>   | <b>Description/Options</b>   | <b>Example</b>  | <b>Vendor-Specific Notes</b> |
|---|-----------------|--|---|------------------------------|
| Number of new partnerships formed this month                  | Number          | Number of new partnerships formed in the past month                    | 3   |                              |
| Number of continued partnerships                              | Number          | Number of partnerships continued from prior months                     | 3   |                              |
| Name of new or continued partner                              | Name            | Name of partner, type of partner                                       | West Texas Community Center                                     |                              |
| Category of new or continued partner                          | Category        | Type of new partner – for example CBO, LHD, FQHC, RHC, other           | Community based organization (CBO)                              |                              |
| Nature of new or continued partnership/collaboration          | Short answer    | Short description of partnership activities                            | Collaborated to hold two vaccination events at community center |                              |
| Number of new outreach campaigns                              | Number          | Number of new outreach campaigns                                       | 3   |                              |
| Number of continuing outreach campaigns                       | Number          | Number of continued outreach campaigns                                 | 3   |                              |
| Name of new outreach campaigns                                | Name            | Campaign name  | Vaccinations for All  |                              |
| Category of new outreach campaigns                            | Category        | Format, for example TV, radio, social media, print, other              | Social media  |                              |
| Reach for campaign  | Number and type | Number of unique views, clicks, listens, shares, or potential audience | 50,000 views  |                              |
| Number of outreach events held in past month                  | Number          | Number of events   | 1   |                              |
| Detail about events (topic, location, partnership involved if | Short answer    | Short description of event   | Held two vaccination events at community center, attended by    |                              |

|   |              |   |  |  |
|---|--------------|---|--|--|
| any, # attendees, outcomes)   |              |   | 500 people, and vaccinated 50 people   |  |
| How are you using data to target and enhance outreach and uptake of vaccine and therapeutics among uninsured persons in your community? | Short answer | Short description of data use                     | Using CDC SVI to find communities of interest  |  |
| What specific data sets and elements are you using?   | Names        | Names of data elements                            | CDC SVI tool   |  |
| Any data challenges or areas where additional data would be helpful?  | Short answer | Short description of data challenges              | Having trouble finding new community-based organizations to partner with in Staten Island and Queens |  |
| Any data sets or elements that have proven particularly helpful?  | Short answer | Short description of data that has proven helpful | Pharmacy desert data provided by CDC team  |  |
| Challenges, risks, and mitigation strategies during the reporting period  |              |   |  |  |
| Successes and lessons learned during the reporting period   |              |   |  |  |
| Financial risks and mitigation strategies discovered during the reporting period  |              |   |  |  |

## Attachment J.1 - Data Reporting Requirements

Testing data enumerated in sections A through C below shall be reported daily to the HHS Protect system or other system designated by the Government. Test result and patient data shall be reported in HHS Protect within 24 hours of receipt of result interpretation.

### A. Test-Related Fields

| Field Name          | Format                              | Description/Options  | Example                       |
|---------------------|-------------------------------------|--|-------------------------------|
| Resulted Date       | MM/DD/YYYY                          | The date the sample is resulted.   | 11/01/2021                    |
| Facility ID         | Defined by Contractor or Government | Unique identifier for each site. Contractor shall obtain approval from the Government for the Facility ID. | P2000                         |
| Collected Date      | MM/DD/YYYY                          | The date the sample was collected  | 11/01/2021                    |
| Test Results        | String                              | Positive, Negative, Indeterminate  | Positive                      |
| Test Type           | String                              | Options to be defined by the Government  | Swab and Send                 |
| Test ID             | String                              | Unique identifier for each test to prevent duplicate result submission                                     |                               |
| Budgetary Test Type | String                              | Options to be defined by the Government to aid in reconciling invoices submitted by the Contractor         | Point-of-Care Test - Pharmacy |
| extended_hours      | String                              | Yes or no if test was conducted outside pharmacy core hours; contractor-dependent.                         | Yes                           |
| test_provided       | String                              | Yes or no if government provided the test.   | Yes                           |
| site_management_fee | String                              | Yes or no if test incurs a surge site management fee.  | Yes                           |
| support_services    | String                              | Yes or no if vendor provided testing support services, contractor-dependent.                               | Yes                           |

### B. Patient-Related Fields

| Field Name               | Format                      | Description/Options   | Example         |
|--------------------------|-----------------------------|---|-----------------|
| Patient Residence County | County name                 | The county (not the city) where the patient resides.  | Harris          |
| Patient Residence State  | 2-letter state abbreviation | The state where the patient resides.  | TX              |
| Age                      | Single year age 0-120       | The age of the patient at the time of the test. Ages 85+ will be aggregated upon ingestion to the data system.                            | 32              |
| Patient Gender           | String                      | Male, Female, Other, Not Reported   | Female          |
| Patient Race             | String                      | American Indian or Alaska Native; Asian; Black or African American; Native Hawaiian or Other Pacific Islander; White; Other; Not Reported | Asian           |
| Patient Ethnicity        | String                      | Hispanic/Latino; Non-Hispanic/Latino; Not Reported  | Hispanic/Latino |
| Patient ID               | String                      | Unique identifier for the patient, if available, subject to the condition that the identifier cannot be linked back to the patient        |                 |
| insurance_status         | String                      | Private Insurance, Medicaid, Medicare, Uninsured  | Uninsured       |

### C. Screening Questions Fields

| Field Name             | Format | Description/Options                       | Example      |
|------------------------|--------|---|--------------|
| Patient Symptom Status | String | Result of patient screening question that | Asymptomatic |

|                                  |                                      |   |                 |
|----------------------------------|--------------------------------------|---|-----------------|
|                                  |                                      | enumerates a set of COVID-19-related symptoms. If the patient selects one or more symptoms, they are deemed Symptomatic. If not, they are deemed Asymptomatic.  |                 |
| Patient Exposure                 | Yes/No                               | Result of patient screening question that seeks to identify if a patient is a close contact of a confirmed case of COVID-19.  | Yes             |
| Patient Travel                   | Yes/No                               | Result of patient screening question that seeks to identify if a patient has recently traveled or will travel in the near future.   | No              |
| Patient Underlying Conditions    | Yes/No                               | Result of patient screening question that enumerates a set of underlying conditions that are thought to increase risk for severe COVID-19 infection. If the patient selects one or more conditions, the result is Yes. If not, the result is No.  | No              |
| Patient Immunocompromised Status | Yes/No                               | Result of patient screening question that enumerates a set of underlying conditions that are thought to indicate immunocompromised status. If the patient selects one or more conditions, the result is Yes. If not, the result is No.  | Yes             |
| Patient Pregnancy Status         | Yes/No                               | Result of patient screening question that seeks to identify if the patient is pregnant.   | Yes             |
| Patient Vaccination Status       | Yes/No                               | Result of patient screening question that seeks to identify if the patient has received one or more COVID-19 vaccination doses.   | Yes             |
| Patient Doses Received           | 1, 2, 3                              | Result of patient screening question that seeks to identify number of COVID-19 vaccination doses received. If patient is not vaccinated, field is left blank. The Government reserves the right to change the number of doses captured in this question subject to FDA and CDC guidance on booster doses. | 2               |
| First vaccine type               | Pfizer-BioNTech, Moderna, J&J, Other | Result of patient screening question that seeks to identify the manufacturer of each vaccination dose. If patient is not vaccinated, field is left blank. The Government reserves the right to change the number of doses captured in this question subject to FDA and CDC guidance on approved vaccines. | Pfizer-BioNTech |
| Second vaccine type              | Pfizer-BioNTech, Moderna, J&J, Other | Result of patient screening question that seeks to identify the manufacturer of each vaccination dose. If patient is not vaccinated, field is left blank. The Government reserves the right to change the manufacturers in this question subject to FDA and CDC guidance on approved vaccines.            | Pfizer-BioNTech |
| Third vaccine type               | Pfizer-BioNTech, Moderna, J&J, Other | Result of patient screening question that seeks to identify the manufacturer of each vaccination dose. If patient is not vaccinated, field is left blank. The Government reserves the right to change the manufacturers in this question subject to FDA and CDC guidance on approved vaccines.            | Pfizer-BioNTech |

|  |                                      |  |                 |
|--|--------------------------------------|--|-----------------|
| Fourth vaccine type                    | Pfizer-BioNTech, Moderna, J&J, Other | Result of patient screening question that seeks to identify the manufacturer of each vaccination dose. If patient is not vaccinated, field is left blank. The Government reserves the right to change the manufacturers in this question subject to FDA and CDC guidance on approved vaccines. | Pfizer-BioNTech |
| First vaccination date                 | Month and year of vaccination        | Result of patient screening question that seeks to identify the time of each vaccine dose. If patient is not vaccinated, field is left blank. The Contractor shall report this to the Government in the form of MM/01/YYYY.  | 10/01/2021      |
| Second vaccination date                | Month and year of vaccination        | Result of patient screening question that seeks to identify the time of each vaccine dose. If patient is not vaccinated, field is left blank. The Contractor shall report this to the Government in the form of MM/01/YYYY.  | 10/01/2021      |
| Third vaccination date                 | Month and year of vaccination        | Result of patient screening question that seeks to identify the time of each vaccine dose. If patient is not vaccinated, field is left blank. The Contractor shall report this to the Government in the form of MM/01/YYYY.  | 10/01/2021      |
| Fourth vaccination date                | Month and year of vaccination        | Result of patient screening question that seeks to identify the time of each vaccine dose. If patient is not vaccinated, field is left blank. The Contractor shall report this to the Government in the form of MM/01/YYYY.  | 10/01/2021      |
| Two weeks since last dose?             | Yes/No                               | Result of patient screening question that seeks to identify, when final dose of vaccination was received in the current or previous month, if the dose was at least two weeks in the past. If patient was vaccinated prior to the previous month or is unvaccinated, field is left blank.      | Yes             |
| Patient past positive test             | Yes/No                               | Result of patient screening question that seeks to identify if the patient has tested positive for COVID-19 in the past.   | No              |
| Patient positive test within 90 days   | Yes/No                               | Result of patient screening question that seeks to identify if the patient has tested positive for COVID-19 in the past 90 days. If patient has never tested positive for COVID-19, field is left blank.   | Yes             |
| Patient positive test prior to 90 days | Yes/No                               | Result of patient screening question that seeks to identify if the patient has tested positive for COVID-19 prior to the past 90 days. If patient has never tested positive for COVID-19, field is left blank.   | Yes             |

A draft of the screening questions provided by the Government is included in this Statement of Work under Exhibit A, ICATT Pharmacy Screening Questions. The Contractor shall use these screening questions in the wording provided by the Government. However, the Contractor may consult with the Government on modifying question wording or response options to suit its testing circumstances.

The Contractor may ask additional screening questions subject to the following conditions:

- The Government-provided screening questions are the first screening questions asked.
- Additional questions are approved by the Government.

The Contractor may report additional fields upon Government approval. The Contractor is not required to report the results of additional questions that it may ask.

**D. Testing Site Data**

Testing site data shall be reported by the Contractor to the Government in advance of the site beginning testing. Testing at any site is subject to Government approval. Testing site data shall be reported by the Contractor to the HHS Protect system or other system designated by the Government.

| <b>Field Name</b> | <b>Format</b>                       | <b>Description/Options</b>   | <b>Example</b> |
|-------------------|-------------------------------------|--|----------------|
| Facility ID       | Defined by Contractor or Government | Unique identifier for each site. Contractor shall obtain approval from the Government for the Facility ID.         | P2000          |
| Subcontractor     | String                              | If Contractor has a Subcontractor arrangement, the Contractor will identify their Subcontractor to the Government. | Topco-eTN      |
| Site Description  | String                              | Description of testing site to include relevant details at discretion of Government and Contractor.                | Store #10000   |
| Address           | Address                             | Address of testing site  | 100 S Main St  |
| City              | City                                | City of testing site   | Houston        |
| State             | Two-letter state abbreviation       | State of testing site  | AK             |
| ZIP Code          | ZIP                                 | 5-digit ZIP code of testing site   | 10000          |
| Go Live Date      | MM/DD/YYYY                          | Date site will begin testing.  | 11/01/2021     |

**E. Over-the-Counter Test Sales**

Under an executed data use agreement, the Contractor shall provide to the Government aggregate sales data related to over-the-counter COVID-19 tests. The Contractor shall provide at least aggregated national sales data on a weekly basis by count of item(s) sold. If available, the Contractor shall provide sales data at the state and/or distribution center level. If available, the Contractor shall provide data on inventory in stock. Over-the-counter sales data shall be reported via email to the Government or its designee, to the HHS Protect system, or to another system designated by the Government.

**F. Site Metadata**

The Contractor shall provide the Government with the operating hours of its testing sites. The Contractor shall provide the Government information on the testing capacity available at its sites, including, if available, information on the number or percentage of appointments dedicated to ICATT-funded tests. The Contractor shall provide the Government information on the tests available for patients at each of its testing sites (e.g. POC, lab-based PCR).

**Exhibit A: ICATT Pharmacy Screening Questions**

|    | <b>Question</b>  | <b>Response Options</b>  | <b>Reporting Field Name</b>  | <b>Reporting Field Options</b>              |
|----|--|--|--|---|
| 1. | In the last 14 days, have you experienced any of these symptoms? Select all that apply.  | fever<br>cough<br>shortness of breath<br>recent loss of sense of smell or taste<br>muscle pain<br>fatigue<br>chill<br>headache,<br>sore throat<br>congestion/runny nose<br>vomiting<br>diarrhea (checkbox, select all that apply)  | symptom_status   | Asymptomatic<br>Symptomatic<br>Not Reported |
| 2. | In the last 14 days, have you had contact with someone who has a suspected or confirmed case of COVID-19? Count any contact that lasted longer than 15 minutes, closer than 6 feet away. | Yes/No   | recent_contact   | Yes<br>No<br>Not Reported                   |
| 3. | Are you seeking a COVID-19 test because you have either recently returned from travel or are planning on traveling soon?   | Yes/No   | traveling  | Yes<br>No<br>Not Reported                   |
| 4. | Has a healthcare worker ever diagnosed you with any of the following? Select all that apply.   | Heart conditions<br>High blood pressure<br>Overweight or obesity<br>Diabetes<br>Current or former smoker<br>Kidney failure or end stage renal disease<br>Cirrhosis of the liver<br>Chronic lung disease, such as COPD, moderate to severe asthma, cystic fibrosis, or pulmonary embolism<br>Immunocompromised state, such as from immunocompromising medications, solid organ or blood stem cell transplant, HIV, or other immunocompromising conditions (checkbox, select all that apply) | underlying_conditions<br>(If any box other than immunocompromised state checked) | Yes<br>No<br>Not Reported                   |
|    |  |  | immunocompromised<br>(If immunocompromised checked)                              | Yes<br>No<br>Not Reported                   |
| 5. | Are you pregnant?  | Yes/No   | pregnant   | Yes<br>No<br>Not Reported                   |
| 6. | Have you had a COVID-19 vaccine?   | Yes/No   | has_received_vaccine   | Yes<br>No                                   |



|   |  |  |  |
|---|--|--|--|
|   |  |  | Not Reported   |
| <i>If yes:</i>  |  |  |  |
| 6a.   | How many doses have you received?                  | 1 / 2 / 3 / 4 (bubbles)  | received_doses<br>1<br>2<br>3<br>4<br>Not Reported   |
| <i>For each dose:</i>                                       |  |  |  |
| 6b.   | Which vaccine have you had?                        | Pfizer-BioNTech, Moderna, Johnson & Johnson / Janssen, Other (bubbles)         | first_vaccine_type<br>second_vaccine_type<br>third_vaccine_type<br>fourth_vaccine_type<br>Pfizer-BioNTech, Moderna, J&J, Other<br>Not Reported |
| 6c.   | Time of shot                                       | Month and year (drop downs)  | first_vaccination_date<br>second_vaccination_date<br>third_vaccination_date<br>fourth_vaccination_date<br>First of the month                   |
| <i>If final shot received in current or previous month:</i> |  |  |  |
| 6d.   | Has it been two weeks since your most recent dose? | Yes/No   | two_weeks_since_dose<br>Yes<br>No<br>Not Reported  |
| 7.  | Have you tested positive for COVID-19 in the past? | Yes/No   | past_positive_test<br>Yes<br>No<br>Not Reported  |
| <i>If yes:</i>  |  |  |  |
| 7a.   | Did you receive this positive test...              | Within the last 90 days, Prior to the last 90 days (checkbox, can select both) | past_positive_test_within_90_days<br>past_positive_test_prior_to_90_days<br>Yes<br>No<br>Not Reported  |

**Notes:**

- Please continue to ask any other questions necessary for CARES Act reporting requirements or other state-mandated requirements.
- ICATT requests any data pharmacies have on completion rates of the existing screeners. ICATT will conduct an analysis of this data before and after implementation of the revised questions in partnership with each pharmacy partner if desired.
- ICATT requests that this screener be implemented as soon as possible and that the timeline of implementation be communicated to ICATT.